



























































injury	 (TISCI),	 yet	 till	 2012,	 it	 had	 not	 been	 defined	 as	 the	 incidence	 of	 cardiac	
events	 and	 rise	 in	 cardiac	 biomarkers	 following	 traumatic	 injury.	 Despite,	






incidence	 of	 adverse	 cardiac	 events	 (ACE)	 with	 consistently	 raised	 serum	 h-FABP	
levels	 in	these	patients.	H-FABP	was	found	to	be	a	good	predictor	of	ACE	through	
ROC	analysis	and	a	h-FABP	of	16.8	ng/ml	used	to	define	trauma	induced	secondary	
cardiac	 injury	 (TISCI).	 TISCI	 was	 associated	 with	 longer	 hospital	 stay	 and	 higher	
mortality.	Patients	who	developed	ACE	had	higher	plasma	levels	of	adrenaline	and	




FABP	 in	 our	 group’s	 trauma	 hemorrhage	 murine	 models.	 The	 hearts	 of	 these	
models	were	used	 in	 the	 experiments	 that	 form	 the	 last	 experimental	 chapter	 of	
this	 thesis.	 Protein	 expression	 studies	 confirm	 this	 increase	 in	 serum	 h-FABP	 by	
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evidence	 of	 concurrent	 leaching	 in	 the	 cardiac	 tissue,	 along	 with	 Troponin	 I.	
Myocardial	 injury	was	evident	on	electron	microscopy	with	evidence	of	 interstitial	
and	 organelle	 oedema,	 myofibrillar	 degeneration,	 nuclear	 condensation	 and	
changes	in	mitochondrial	morphology.	Immunohistochemistry	and	western	blotting	
protein	 studies	 demonstrate	 the	 translocation	 of	 the	mitochondrial	 death-related	




and	 outcomes	 in	 critically	 injured	 patients.	 Although	 increasing	 serum	
noradrenaline	 and	 adrenaline	 levels	 are	 associated	 with	 higher	 incidence	 of	 ACE	
and	 biochemical	 evidence	 of	 cardiac	 injury	with	 rising	 h-FABP	 levels,	multivariate	
analysis	negates	their	value	as	independent	predictors	of	ACE.	Leaching	out	of	the	
proteins	h-FABP	and	Troponin	I	in	the	murine	cardiac	tissue	confirmed	the	value	of	
serum	 measurements	 of	 these	 proteins	 as	 markers	 of	 cardiac	 injury.	 This	 was	
associated	with	widespread	ultrastructural	myocardial	damage	in	the	TH	mice	with	
changes	 in	 mitochondrial	 morphology.	 The	 mitochondrial	 damage	 seen	 is	
associated	with	the	translocation	of	the	mitochondrial	death-related	protein	AIF	to	
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Injury	 is	 defined	 as	 the	 transfer	 of	 energy	 leading	 to	 tissue	 damage.	 This	 still	
remains	 a	 pertinent	 global	 health	 issue,	 contributing	 to	 9%	 of	 global	 mortality,	
which	translates	to	5	million	deaths	every	year	(1).	It	is	the	leading	cause	of	death	in	
young	 people	 in	 the	 UK,	 with	 a	 total	 of	 48000	 cases	 of	major	 trauma	 each	 year	
resulting	in	19500	deaths(2).		
	
Road	 traffic	 accidents	 (RTA)	 alone	 account	 for	 24%	 of	 trauma	 deaths	 and	 are	
predicted	 to	 be	 the	 fifth	 leading	 cause	 of	 mortality	 by	 2030.	 About	 1.25	 million	
deaths	 a	 year	 occur	 due	 to	 RTA	 injuries,	with	 20-	 50	million	more	 suffering	 from	
non-fatal	injuries	(3).	It	is	estimated	that	3500	lives	are	lost	each	day	secondary	to	
RTAs.	 Unsurprisingly,	 there	 is	 a	 large	 incongruence	 in	 mortality	 rates	 between	
economic	 regions	 worldwide.	 Despite	 owning	 only	 56%	 of	 registered	 vehicles	




countries	of	 the	Americas	 there	has	been	a	5%	 increase	with	 incidence	 rates	 that	
are	 four	 fold	 higher	 than	 the	 global	 average	 (3).	 Trauma	 also	 contributes	 to	 a	
greater	 disease	 burden	 in	 this	 population	 owing	 to	 high	 rates	 of	 violence	 against	
women	and	homicide,	with	75%	attributed	to	gun	crime	(3).		
	











Although	 trauma	 only	 contributes	 to	 0.2%	 of	 A&E	 workload,	 its	 immediate	
treatment	costs	more	than	£300	million	with	annual	economic	output	estimated	to	
be	 in	 between	£3.3-3.7	 billion	 (2).	Worldwide	 injuries	 lead	 to	 a	 loss	 of	 3%	of	 the	
global	gross	domestic	product	(4).		
	
Despite	 the	 global	 improvements	 in	 outcome,	 trauma	 still	 remains	 a	 significant	
burden	on	health	and	socioeconomic	outcomes	in	the	UK	and	worldwide.		









The	 advent	 of	 the	 London	 Trauma	 System	 (LTS)	 and	 its	 introduction	 of	 triaging	
patients	to	specialised	Level	I	trauma	centres	has	led	to	significant	improvements	in	
patient	outcomes	in	a	short	period	of	time	(9).	In	just	over	3	years,	mortality	within	
the	 first	 72	 hours	 reduced	 from	 14%	 to	 7%.	 The	 establishment	 of	 the	 LTS	 was	
preceded	 by	 the	 development	 of	 major	 haemorrhage	 protocols	 involving	
optimisation	of	transfusion	practices,	the	use	of	tranexamic	acid	and	the	promotion	
of	 damage	 control	 resuscitation	 and	 surgery	 all	 being	 central	 to	 the	 reduction	 in	
mortality	and	improvement	in	trauma	care	(9).		
	
On	 hospital	 admission,	 patients	 who	 survive	 the	 acute	 post	 injury	 phase,	 have	 a	
greater	risk	of	developing	multiple	organ	dysfunction	(MODs)	during	their	hospital	
admission.	 Improvements	 in	 critical	 care	 protocols	 have	 significantly	 reduced	 the	
incidence	 of	 MODs	 over	 time,	 however	 mortality	 remains	 unchanged	 (7,10).	 In	
patients	who	develop	MODs,	although	deaths	primarily	due	to	cardiac	dysfunction	
have	declined,	 it	 still	 contributes	 to	MODs	 in	5%	of	 the	non-survivors(10,11).	 In	a	
large	study	of	 the	German	Trauma	registry,	Frohlich	2013	showed	that	circulatory	




when	 compared	 to	 gender	 and	 age	 matched	 non-injured	 group	 (10-14).	





haemorrhage	 comes	 from	 rodent	 models.	 Professor	 Chaudry’s	 group	 has	
significantly	contributed	to	this	field	since	1993.	They	have	focused	on	depression	in	
myocardial	 function	 and	 explored	 the	 mechanistic	 contribution	 of	 sex	 hormones	
and	 inflammatory	 proteins.	 Their	 model	 uses	 rats	 that	 are	 anaesthetised	 with	
methoxyfluorane	and	subjected	to	a	5	cm	midline	laparotomy.	Vascular	access	lines	
are	placed	 in	 the	carotid	artery,	 femoral	artery	and	 femoral	 vein	and	 the	 rodents	
are	 bled	 to	 a	mean	 arterial	 pressure	 of	 40mmHg.	 Initial	 resuscitation	 is	 with	 the	
withdrawn	 blood	 and	 Ringer’s	 lactate	 over	 60	 minutes.	 Their	 model	 exhibits	 a	
reduction	 in	 left	 ventricular	 function	 as	measured	 by	 a	 reduction	 in	 the	maximal	
rate	of	pressure	in	the	left	ventricle,	ventricular	peak	systolic	pressure	and	cardiac	
output.	 (15-21).	 Mechanistically,	 the	 group	 demonstrated	 that	 an	 estrus	 state	
attenuates	the	deleterious	effects	of	trauma	haemorrhage	(TH)	on	cardiac	function	
(15-25).	They	also	showed	that	progesterone	and	castration	mitigated	the	reduction	
in	 cardiac	 function	 through	 reduction	 in	 testosterone	 levels	 (15,26,27).	 	 Further	




production	 of	 various	 cytokines	 and	 cell	 adhesion	 molecules	 (28).	 These	






ischaemia	 and	 arrhythmias	 have	 been	 previously	 studied	 in	 trauma	 patients	 but	
furthermore	 studies	 have	 investigated	 the	 relevance	 of	 cardiac	 biomarkers	 in	
trauma	patients.	These	will	be	discussed	later	in	Section	1.6.4.	
	
In	 a	 retrospective	 case	 note	 study	 conducted	 by	 Ismailov	 et	 al.,	 the	 incidence	 of	
acute	 myocardial	 infarction	 (AMI)	 in	 trauma	 patients	 was	 found	 to	 be	 3%,	 and	
associated	with	thoracic	injury,	abdominal	and	pelvic	injuries.	Further	examination	
through	 logistic	 regression	 revealed	 that	 in	 patients	 less	 than	 45	 years	 old,	
abdominal	and	pelvic	injuries	were	associated	with	65%	increased	risk	of	developing	
AMI.	They	also	 found	 that	blunt	 cardiac	 injury	was	an	 independent	 risk	 factor	 for	
dysrhythmias,	however,	 thoracic	 injury	was	not	an	 independent	risk	 factor.	 In	 this	
cohort,	patients	younger	than	50	years	had	a	four-fold	increase	in	risk	of	developing	
arrhythmias	 (29).	 In	 younger	 patients	with	 less	 likelihood	of	 underlying	 ischaemic	
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heart	 disease	 and	 the	 increase	 in	 risk	 seen	 with	 abdominal	 and	 pelvic	 injuries	
potentially			
	




insertion	 of	 pulmonary	 artery	 catheters	 were	 all	 risk	 factors.	 Furthermore,	 they	
demonstrated	 that	direct	 thoracic	 injury	 led	 to	a	17-fold	 increase	 in	 risk.	 In	2006,	






the	patients	who	developed	atrial	 arrhythmias	 (AA)	were	older,	more	 likely	 to	be	
male,	more	 severely	 shocked	 on	 admission	 and	 had	 a	 higher	 prevalence	 of	 blunt	








	In	 2012,	 our	 group	 conducted	 a	 retrospective	 study	 on	 a	 panel	 of	 cardiac	
biomarkers	 in	 a	 cohort	 of	 135	 patients.	 In	 this	 study,	 13%	 patients	 had	 adverse	
cardiac	 events	 (ACE).	 In	 the	 patients	 who	 developed	 ACEs,	 serum	 h-FABP	 levels	
were	 three	 times	 higher	 and	 BNP	 levels	 were	 1.5	 times	 higher	 and	 this	 was		
associated	 with	 greater	 injury	 severity	 and	 shock.	 The	 rise	 in	 cardiac	 biomarkers	
was	 not	 associated	 with	 thoracic	 injury	 nor	 head	 injuries.	 There	 was	 also	 no	
difference	 in	 pre-existing	 diseases	 such	 as	 hypertension,	 hypercholesterolaemia,	




ACEs	 (33).	 In	 this	 study,	 patients	 with	 higher	 levels	 of	 circulating	 inflammatory	
cytokines	–	tumor	necrosis	factor	(TNF)	α,	interleukin	(IL)-6	and	IL-8	had	a	hundred-
fold	 increase	 in	 serum	 heart	 fatty	 acid	 binding	 protein	 (h-FABP).	 Multivariate	
analysis	also	revealed	that	age,	injury	severity	score	(ISS)	and	IL-6	were	independent	
predictors	of	myocardial	damage,	as	predicted	by	h-FABP.	This	study	also	found	that	
patients	 admitted	 with	 raised	 levels	 of	 troponin	 I	 and	 elevated	 inflammatory	
cytokine	had	increased	risk	of	mortality(33).		
	
This	 was	 the	 first	 study	 designed	 to	 examine	 the	 possibility	 of	 identification	 of	
cardiac	 injury	and	prognostication	 in	trauma	patients	using	a	panel	of	biomarkers.	
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Although	retrospectively	conducted,	it	demonstrated	the	rise	of	cardiac	biomarkers	




Myocardial	 injury	 is	 diagnosed	 using	 a	 combination	 of	 clinical	 features.	 It	 may	
manifest	 clinically	 as	 chest	 pain,	 palpitations,	 syncope	 or	 cardiovascular	 collapse.	
These	 are	 often	 seen	 in	 addition	 to	 electrocardiogram	 (ECG)	 changes	 such	 as	 ST	
elevation,	arrhythmias,	conduction	abnormalities	such	as	bundle	branch	blocks	and	










contraction	 of	 the	myocyte.	 It	 is	made	 up	 of	 the	 calcium	binding	 troponin	 C,	 the	
inhibitory	(Cardiac	Troponin	I)	cTnI	(23	kDa)	and	the	tropomyosin	binding	Troponin	
T	(37kDa).	Current	assays	are	cardiospecific	and	targeted	at	the	cardiac	isoforms	of	
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Troponin	 I	 and	 T.	 During	 development	 of	 myocardial	 ischaemia,	 the	 troponin	
subunits	 are	 released	 from	 the	 contractile	 apparatus	 and	 leak	 through	 the	 cell	




serum	 concentration	 of	 less	 than	manufacturers	 reference	 value	 followed	by	 less	





The	 development	 of	 right	 ventricular	 strain	 and	 cardiac	 dysfunction	 is	 a	 poor	
prognostic	indicator	in	patients	with	pulmonary	embolism.	Raised	cTnI	levels	in	PE	
has	 been	 associated	 with	 cardiac	 dysfunction,	 increased	 rates	 of	 serious	 adverse	
event	 (SAE)	 and	 mortality	 (38,39).	 Identifying	 these	 patients	 for	 prompt	
thrombolysis	has	been	suggested	for	improving	patient	outcomes	(Beccattini	2007).		
	
In	 sepsis,	 system	 inflammatory	 response	 syndrome	 (SIRS)	 and	 its	 associated	
hypotension,	hypoperfusion	and	tachycardia	have	all	been	 indicated	to	contribute	
to	 increased	myocardial	 stress(8).	 In	 line	 with	 this,	 SIRS	 has	 also	 been	 shown	 to	
induce	reversible	as	well	as	irreversible	cardiac	dysfunction	(6).		Furthermore,	cTnI	
has	been	shown	to	be	higher	in	patients	admitted	to	intensive	care		unit	(ICU)	with	
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septic	 shock,	 and	 correlates	 with	 left	 ventricle	 (LV)	 dysfunction	 and	 associated	
poorer	outcomes	(40-43).	A	meta-analysis	of	162	studies	on	the	predictive	value	of	
cTnI	 on	 mortality	 in	 septic	 patients	 revealed	 that	 raised	 cTnI	 concentration	 was	
associated	with	a	two-fold	increase	in	mortality,	however,	it	was	not	found	to	be	an	





The	myocardium	 is	 exposed	 to	multiple	 deleterious	 factors	 during	 critical	 illness.	










Brain	 type	 natriuretic	 peptide	 (BNP)	 is	 a	 37	 kDa	 cardiac	 neurohormone	 that	 is	
systhesised	 in	 the	 ventricular	 myocardium	 and	 secreted	 into	 the	 bloodstream	 in	
response	to	myocardial	stretch.	Stretch	stimuli	leads	to	an	immediate	increase	in	its	




longer	 half-life	 and	 therefore	 remains	 in	 the	 bloodstream	 longer	 than	 BNP.	 The	
active	 BNP	 	 acts	 on	 natriuresis,	 smooth	 muscle	 relaxation,	 inhibition	 of	 renin-
angiotensin	 system	 and	 inhibition	 of	 sympathetic	 activity(47).	 BNP	 has	 been	
primarily	used	 in	the	diagnosis	of	acute	and	chronic	heart	 failure	(48).	 It	has	been	
shown	to	be	useful	in	the	prognostication	in	AMI,	with	higher	levels	associated	with	




The	 increase	 in	pulmonary	 venous	pressure	 in	PE	 leads	 to	 raised	 right	 ventricular	
pressure	 causing	 to	myocardial	 stretch.	Multiple	 prospective	 studies	 have	 shown	
that	nt-proBNP	correlates	well	with	the	development	of	serious	adverse	events	 in	
PE	 (39,52-57).	 A	meta-analysis	 of	 studies	 investigating	nt-proBNP	 in	 PE	 found	 the	
combined	 OR	 for	 mortality	 to	 be	 6.2	 (58).	 Higher	 levels	 were	 associated	 with	
increased	 rates	 of	 inotropic	 support,	 intubation	 and	 mortality.	 In	 a	 prospective	
study	 of	 113	 patients	 with	 PE,	 nt-proBNP	 was	 almost	 six	 times	 higher	 at	 10,678	
ng/ml	in	the	non-survivors	compared	to	1895	in	the	survivors.		A	persistently	raised	
nt-proBNP	 level,	 with	 circulating	 concentrations	 of	 >7500	 ng/ml	 that	 remained	
raised	at	24	hours	was	 found	 to	be	 the	 strongest	predictor	of	mortality	 (56).	 The	
same	 research	 group	went	on	 to	 compare	 the	 efficacy	of	 nt-proBNP	and	 cTnI	 for	
risk	 stratification	 of	 normotensive	 patients.	 In	 their	 risk	 stratification	model,	 they	
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In	 sepsis,	 an	 increase	 in	 serum	 BNP	 levels	 has	 been	 associated	 with	
echocardiographic	changes	of	reversible	and	sustained	cardiac	dysfunction	(60)	(11)	
(61)	(11,60,61).	Raised	BNP	levels	 leads	to	an	8-fold	 increase	 in	mortality	 in	septic	
patients(62).		It	was	noted	to	be	a	moderate	predictor	of	mortality	in	sepsis	with	a	
AUC	 of	 0.65	 on	 ROC	 analysis.	 These	 raised	 BNP	 levels	 used	 in	 combination	 with	
clinical	acumen	could	help	delineate	patients	at	greater	risk	of	adverse	outcomes.	




Heart	 related	 fatty	 acid	 binding	 protein	 (h-FABP)	 is	 a	 relatively	 new	 cardiac	
biomarker;	 first	 discovered	 as	 a	marker	 of	myocardial	 injury	 in	 1988.	 It	 is	 a	 small	
14kDa	 cytosolic	 protein	 that	 acts	 a	 transporter	 of	 fatty	 acids	 from	 the	 cell	
membrane	to	the	mitochondria	for	oxidation.	 It	 is	released	as	early	as	90	minutes	
post	 myocardial	 ischaemia,	 reaching	 peak	 concentrations	 within	 the	 plasma	 at	 6	
hours.	Values	of	6-7	ng/ml	are	considered	to	be	indicative	of	cardiac	ischaemia.	In	
AMI,	it	has	been	shown	to	exhibit	greater	sensitivity	in	comparison	to	troponin	with	
a	better	negative	predictive	value,	however	due	 to	 its	 lack	of	 specificity,	 troponin	
remains	the	gold	standard	for	the	diagnosis	of	AMI.	Furthermore,	Cardiac	TnI	was	












tool	 in	 prognostication.	 In	 PE,	 it	 has	 been	 shown	 to	 be	 raised	 in	 patients	 who	
develop	adverse	outcomes	and	those	who	die	within	30	days	of	admission	(70-73).	
Raised	 h-FABP	 levels	 on	 admission	 was	 related	 with	 a	 17-fold	 increased	 risk	 of	
developing	adverse	outcomes	and	33-fold	risk	of	mortality	(74).		Higher	levels	of	h-




levels	 in	 intermediate	 risk	 PE	 patients,	 thrombolysed	 according	 to	 current	
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In	 sepsis,	 h-FABP	 levels	 on	 admission	 to	 critical	 care	 units	 (CCU)	 predict	
development	of	organ	dysfunction	and	mortality	with	greater	 accuracy	 than	 cTnI.	
Patients	 with	 higher	 h-FABP	 levels	 required	 earlier	 mechanical	 ventilation	 and	
inotropic	 support	 (78).	 There	 was	 no	 difference	 in	 h-FABP	 levels	 In	 those	 who	











on	 clinical	 suspicion,	 ECG	 changes	 and	 cTnI	 levels.	 On	 review	 of	 the	 current	
evidence,	 they	 recommend	 that	blunt	 cardiac	 injury	 (BCI)	 can	be	 ruled	out	 if	 ECG	
and	troponin	I	are	normal.	In	studies	that	looked	at	BCI,	cTnI	levels	of	1.05-	2ng/ml	


















In	 a	 large	 retrospective	 study	 of	 trauma	 patients	 to	 identify	 risk	 factors	 for	 the	
development	of	cardiac	injury	in	trauma	patients	who	develop	sepsis,	patients	who	
had	 troponin	measurements	 during	 their	 admission	were	 identified.	 The	 study	 of	
this	 population	 revealed	 that	 a	 pre-existing	 diagnosis	 of	 chronic	 obstruction	
pulmonary	disease	(COPD),	injury	severity,	ventilator	acquire	pneumonia	(VAP)	and	
urinary	 tract	 infection	 (UTI)	 were	 all	 risk	 factors	 for	 the	 development	 of	 indirect	














In	a	 small	prospective	 study	of	26	patients,	nt-ProBNP	was	 shown	 to	be	 raised	 in	
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a	prospective	study	of	55	poly	 trauma	patients	with	direct	 thoracic	 injury,	h-FABP	
levels	were	higher	in	patients	with	thoracic	injuries	but	not	in	patients	with	cardiac	
injury.	 However,	 the	 author	 does	 not	 clarify	 how	 cardiac	 injury	 was	 defined,	
especially	only	41%	of	patients	had	abnormalities	on	ECG	or	echocardiograms	(92).	
The	use	of	h-FABP	as	a	cardiac	biomarker	will	be	confounded	by	 its	expression	 in	
brain	 tissue.	 In	 a	 small	 but	 insightful	 study	 conducted	 by	walder	 et	 al,	 they	 shed	
some	 light	on	 the	 contribution	of	 traumatic	brain	 injury	 (TBI)	 to	 the	 release	of	h-




in	 the	 isolated	 head	 injury	 group	 was	 not	 explored	 in	 this	 study	 (93).	 This	








The	 stresses	 of	 events	 preceding	 traumatic	 injury	 in	 combination	with	 the	 severe	
injuries	sustained	by	trauma	patients	evoke	a	significant	sympathetic	response	and	
therefore	 a	 catecholamine	 surge.	 In	 this	 study,	 the	 cardiac	 effects	 of	 the	
catecholamines	 release	 will	 be	 explored.	 Similar	 studies	 in	 septic	 patients	 have	










Forensic	 pathologists	 have	 expressed	 academic	 interest	 in	 histological	 changes	 of	
the	 myocardium	 following	 trauma	 for	 decades.	 In	 1980,	 a	 case	 series	 of	 the	
postmortem	 histological	 examination	 of	 15	 homicidal	 victims	was	 published.	 This	
showed	 myofibrillar	 degeneration	 in	 11	 of	 the	 15	 patients	 which	 the	 authors	
attributed	to	stress	induced	catecholamine	release	(100).		In	a	further	postmortem	
study	 of	 24	 trauma	 patients,	 myocardial	 histology	 revealed	 the	 presence	 of	




More	 recently,	 a	 large	 human	 study	 looking	 at	 histological	 changes	 of	 the	
myocardium	 in	 trauma	 patient	 hearts	 postmortem	 has	 demonstrated	 both	
macroscopic	 as	 well	 as	 microscopic	 architectural	 changes.	 Examination	 of	 the	
myocardium	of	125	trauma	patients	demonstrated	a	variety	of	histological	changes	
in	 keeping	 with	 ischaemia	 and	 necrosis	 including	 congestion,	 interstitial	 edema,	
fragmentation	 of	 myocytes,	 haemorrhage,	 leukocytic	 infiltration,	 coagulative	
necrosis,	 hyaline	 degeneration	 of	 myocytes,	 cytoplasmic	 vacuolation,	





Animal	 studies	 have	 demonstrated	 that	 traumatic	 injury	 leads	 to	 cardiomyocyte	
apoptosis(103,104)	 (103);	 (104).	 Mechanistic	 studies	 have	 elucidated	 a	 TNF-α	
driven,	 caspase	 dependent	 pathway	 as	 the	 cause	 for	 this	 myocardial	 apoptosis	
(103).	In	rat	models,	2	hours	of	TH	has	been	shown	to	be	associated	with	increased	
expression	 of	 the	 pro-apoptotic	 protein	 Bax	 and	 reduction	 of	 the	 anti-apoptotic	
protein	 Bcl-2,	 leading	 to	 increased	 cardiomyocyte	 apoptosis	 as	 seen	 on	 H&E.	
Furthermore,	this	correlate	with	creatine	kinase	(CK)	and	lactate	hydrogenase	(LDH)	
as	biomarkers	of	cardiac	injury.	This	study	also	demonstrated	that	administration	of	




reduction	of	 cardiac	 function	was	 corroborated	by	 a	murine	 study	demonstrating	
concurrent	 reduction	 in	 mitochondrial	 function	 with	 reduced	 adenosine	
triphosphate	 (ATP)	 production,	 reduced	 expression	 of	 mitochondrial	 respiratory	
complex	 (MRC)	 proteins,	 increased	 release	 of	 cytochrome	 C	 into	 the	 cytosol	 and	
increased	caspase-3	cleavage	(105).	
Ischaemic	 injury	of	 the	heart	has	been	associated	with	myocardial	necrosis	 (106).	
More	 recently,	 the	 processes	 that	 define	 different	 cell	 death	 mechanisms	 have	
been	noted	 to	cross	over	 (107).	 	Although,	 there	has	been	 interesting	 insight	 into	




The	 release	 of	 cardiac	 structural	 proteins	 such	 as	 cTnI	 and	 h-FABP	 requires	






membrane	 and	 complete	 fragmentation.	 Although,	 historically,	 cell	 death	 was	
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thought	to	occur	either	by	necrosis	or	apoptosis,	 it	has	become	apparent	that	the	
fate	 of	 a	 dying	 cell	 is	 not	 so	 binary	 in	 nature.	 It	 can	 however,	 be	 divided	 into	
accidental	 cell	 death	 and	 programmed	 cell	 death.	 Accidental	 cell	 death	 occurs	
following	 significant	 direct	 exposure	 to	 severe	 adverse	 conditions	 such	 as	 toxins,	
chemicals,	temperature	or	mechanical	 injury.	The	noxious	 insult	 itself	 leads	to	cell	
membrane	lysis,	hence	oedema	of	cell	organelles.	The	pathway	of	the	programmed	




Apoptosis	described	as	a	programmed	cell	death	mechanism	 is	 thought	 to	 reduce	
collateral	 damage	 by	 the	 formation	 of	 apoptosomes,	 which	 are	 then	 cleared	 by	
phagocytosis.	On	electron	microscopy,	apoptosis	 is	characterised	by	deep	staining	
of	 the	nuclear	mass	 (pyknosis)	and	 formation	of	 condensed	cell	bodies	 (apoptotic	
bodies).	 Apoptosis	 can	 be	 further	 differentiated	 to	 death	 receptor	 driven	
(extrinisic/type	I)	or	mitochondria	driven	(intrinsic/type	II).		
1.9.2	Extrinsic	Death	Receptor	Pathway	
The	 extrinsic	 pathways	 are	 dependent	 on	 activation	 of	 death	 domain	 containing	
receptors.	 The	 two	 well-studied	 receptors	 are	 Fas	 Ligand	 receptor	 and	 TNF	
Receptor	(TNFR).	The	activation	of	these	receptors	leads	to	cleavage	of	procaspase	
8	 to	 caspase	 8,	 and	 in	 turn	 the	 activation	 of	 caspase	 3	 and	 7	 and	 thereon	 the	
proteolytic	cleavage	of	proteins	which	leads	to	apoptosis	(106).	TNFα	upregulation	
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is	well	reported	in	trauma	so	extrinsic	pathways	of	apoptosis	may	well	be	at	play.	In	








The	 intrinsic	 cell	 death	 pathways	 are	 initiated	 by	 a	 combination	 of	 external	 and	
internal	 stimuli.	 A	 delicate	 balance	 of	 pro-apoptotic	 and	 anti-apoptotic	 the	 Bcl-2	
proteins	 govern	 the	 intrinsic	 pathways.	 Under	 physiological	 conditions,	 the	 anti-
apoptotic	proteins	of	the	family	maintain	the	integrity	of	the	mitochondria.	Noxious	
external	 stimuli	 and	metabolic	disturbance	within	 the	 cell,	 for	example	 release	of	
reactive	oxygen	species	(ROS)	or	excess	calcium,	leads	to	activation	of	BH3	proteins	
and	 its	 subsequent	 its	 translocation	 from	 the	mitochondria	 to	 the	 cytosol.	 In	 the	
cytosol,	 BH3	 proteins	 act	 to	 either	 directly	 antagonise	 pro-apoptotic	 proteins	 or	
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ROS	 into	 the	 cell	 directly	 leading	 to	 necrosis,	 release	 of	 cytochrome	 C	 causing	
induction	 of	 apoptosis	 through	 caspase	 9	 dependent	 pathways,	 or	 the	 release	 of	
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In	trauma	as	described	above,	the	sequelae	of	events	following	the	initial	impact	of	
the	 injury	 occur	 due	 to	 bleeding	 and	 tissue	 damage.	 Significant	 bleeding	 leads	 to	
poor	 perfusion,	 hypoxia,	 anaerobic	 respiration	 and	 acidosis,	which	 can	 all	 lead	 to	
the	 activation	 of	 the	 intrinsic	 pathway.	 The	 role	 of	 Bcl-2	 has	 been	 highlighted	 in	





Apoptosis	 inducing	 factor	 (AIF)	 is	 a	 mitochondrial	 flavoprotein	 that	 exists	 in	 the	
intermembrane	space	attached	to	the	mitochondrial	inner	membrane.	The	nuclear	
coded	 AIF	 gene	 gives	 rise	 to	 a	 67kDa	 protein	 with	 a	 mitochondrial	 localization	
sequence.	 Maturation	 of	 the	 precursor	 leads	 to	 the	 cleavage	 of	 mitochondrial	
localization	 sequence	 (MLS)	 and	 its	 attachment	 to	 the	 mitochondrial	 inner	
membrane.	Apoptotic	signaling	 leads	to	 its	 further	proteolytic	cleavage	causing	 its	
release	from	the	mitochondrial	 inner	membrane	in	its	57	kDa	truncated	form.	The	
activation	of	the	intrinsic	cell	death	pathway	by	Bcl-2	related	proteins	leads	to	the	
permeabilisation	of	 the	mitochondrial	outer	membrane	 releasing	 the	apoptogenic	
AIF	 into	 the	 cytosol,	 which	 then	 translocates	 to	 the	 nucleus	 where	 it	 leads	 to	
peripheral	 chromatin	 condensation,	 DNA	 fragmentation	 and	 blebbing	 associated	
with	 irregular	 shaped	 nuclei.	 Susin	 et	 al	 demonstrated	 these	 characteristic	
apoptotic	 nuclear	 changes	 in	 healthy	 heLA	 cell	 nuclei	 incubated	 in	 medium	
containing	 AIF	 (110).	 Although	 apoptosis	 occurred	 in	 the	 absence	 of	 cytosolic	
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showing	the	prognostic	value	of	cTnI,	BNP	and	h-FABP	 in	 traumatic	 injury	provide	
good	 founding	evidence	 for	 the	presence	of	myocardial	 injury	 in	 traumatic	 injury.	




Cardiac	biomarker	detection	 in	 trauma	patients	 is	complicated	by	the	presence	of	
multiple	 organ	 injury,	 tissue	 injury	 and	 hypoperfusion.	 In	 order	 to	 explore	 the	
impact	of	trauma	directly	on	cardiac	tissues,	a	murine	model	of	trauma	will	be	used	
to	 allow	 direct	 examination	 of	 cardiac	 tissue	 following	 trauma	 haemorrhage	
through	the	use	of	microscopy	and	protein	analysis.	
	 	




The	 overarching	 goal	 of	 this	 thesis	 is	 to	 further	 the	 understanding	 of	 trauma	
induced	secondary	cardiac	injury	(TISCI).	For	this	purpose,	this	study	aims	to:	
1. Describe	 the	 clinical	 manifestations	 of	 TISCI,	 potential	 risk	 factors	 and	 its	
effect	on	outcomes	
2. Identify	potentialbiomarkers	of	TISCI	

























This	 chapter	 summarises	 the	 materials	 and	 methods	 used	 in	 Chapters	 3-5.	 The	
clinical	 study	 methodologies	 apply	 to	 bother	 chapters	 3	 and	 4	 as	 well	 as	 the	
principles	of	enzyme-linked	immunoassays	(ELISA).	It	is	presented	separately	rather	
than	within	each	chapters	for	ease	of	reference	and	to	avoid	repetition.	Chemicals	












The	 study	 was	 reviewed	 and	 approved	 by	 the	 Cambridge	 3	 Research	 Ethics	
Committee.	(Reference	No.	10/H0306/47)	
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2.2.2	Study	Population	
All	 adult	 patients	 above	 aged	 16	 and	 above,	 who	 triggered	 the	 trauma	 team	
activation	 and	 presented	 with	 an	 abnormal	 primary	 survey	 were	 screened	 for	











• Patients	 were	 retrospectively	 excluded	 if	 they	 or	 a	 personal	 consultee	
declined	to	give	consent	for	the	research	study	
2.2.3.	Consent		

















in	 the	 study	 under	 LAR	 consent.	 Patient	 who	 die	 acutely	 or	 prior	 to	 receipt	 of	
appropriate	LAR	consent	from	a	next	of	kin	can	remain	enrolled	in	the	study	under	
PLAR	 consent.	 A	 database	 logging	 all	 consent	 attempts	 was	 maintained	 to	
document	adherence	to	these	consent	procedures.	
2.2.4	Data	Collection	
Data	 was	 collected	 prospectively	 by	 the	 research	 personnel	 on	 patient	
demographics,	mechanism	of	injury,	 injury	time,	time	of	arrival	 in	the	ED,	baseline	
vital	 signs,	 daily	 physiological	 data,	 Injury	 Severity	 Score	 (ISS),	 Abbreviated	 Injury	
Scale	(AIS),	past	medical	history	and	concomitant	cardiac	medication.	The	patients	
were	reviewed	daily	 to	record	any	occurrence	of	cardiac	events	during	admission,	
the	 length	 of	 stay	 and	 mortality.	 Patients	 with	 adverse	 cardiac	 events	 had	
echocardiograms.	





into	 a	 4·5-ml	 Vacutainer®	 containing	 3.2%	 (0·109	 mol/l)	 buffered	 sodium	 citrate	
(Becton	 Dickinson,	 Plymouth,	 UK).	 Blood	 was	 collected	 on	 admission,	 24	 hours	





being	 transferred	 into	 0·6-ml	 Eppendorf	 tubes	 and	 subsequently	 frozen	 at	 −80°C	
until	 ready	 for	 processing.	 Plasma	 stored	 at	 -80oC	 was	 thawed	 to	 37oC	 prior	 to	
biochemical	analysis.		
	 	





















is	 washed	 and	 a	 chromogenic	 substrate	 such	 as	 tetramethylbenzine	 (TMB)	 was	
added.	After	15-20	minutes	of	 incubation;	an	acid	 is	added	 to	cease	 the	 reaction.	
This	is	an	indirect	visualisation	method	as	the	chromogen	does	not	directly	bind	to	
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the	 antigen	 of	 interest	 but	 to	 its	 corresponding	 detection	 antibody,	 thereby	
increasing	the	specificity	of	the	assay	(111).		
In	a	competitive	ELISA,	the	sample	is	initially	incubated	with	a	specific	antibody	for	
the	 antigen	 of	 interest.	 Then	 this	 sample,	 now	 containing	 antigen-	 antibody	
complexes	 is	 added	 to	 the	 wells	 coated	 with	 purified	 antigen	 of	 interest.	 Any	
unbound	 antibody	 will	 bind	 to	 the	 antigens	 on	 the	 wall	 of	 well.	 So	 higher	 the	







they	 allow	 for	 accurate	 determination	 of	 concentration	 of	 an	 analyte	 in	 a	 crude	
sample,	 even	 without	 prior	 purification.	 The	 competitive	 ELISAs	 are	 useful	 in	
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6. 100	μl	of	TMB	substrate	was	added	to	each	well.		
7. The	 tray	 was	 covered	 with	 foil	 and	 incubated	 for	 15	 minutes	 at	 room	
temperature.		
8. The	reaction	was	stopped	by	adding	100	μl	of	stop	solution	





1. 96	 well	 plates	 used	 were	 labelled	 appropriately	 on	 a	 matching	 schematic	
diagram	along	with	appropriate	Eppendorf	tubes.	
2. Standards	 of	 predetermined	 concentrations	 were	 reconstituted	 with	
distilled	water.	
3. 150	 μl	 of	 assay	 buffer	 is	 added	 to	 all	 wells	 expected	 the	 blank.	 This	 is	
followed	by	30	μl	of	the	standard	or	sample	in	its	respective	wells.		
4. This	is	followed	by	50	μl	of	conjugate	into	each	well	except	the	blank.	
5. The	 plate	 is	 covered	 in	 foil	 and	 incubated	 overnight	 (16-25	 hours)	 in	 the	
fridge	at	4oC	
6. The	 plate	was	washed	 using	 a	 plate	washer.	 300	 μl	 of	washer	 buffer	was	
used	per	wash	and	this	was	repeated	five	times.	On	the	 last	cycle	all	wells	
are	aspirated	
7. Following	 this,	 200	 μl	 of	 substrate	 is	 added	 to	 wash	 well	 and	 the	 plate	
incubated	at	room	temperature	for	20	minutes.		
8. 500	μl	of	stop	solution	is	then	added	to	each	well.	
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2.3.5	Troponin	I	ELISA	
1. 96	 well	 plates	 used	 were	 labelled	 appropriately	 on	 a	 matching	 schematic	
diagram	along	with	appropriate	Eppendorf	tubes.	
























6. Supernatant	 was	 removed	 and	 1ml	 wash	 buffer	 into	 each	 well	 and	
incubated	for	a	further	5min	at	room	temperature	on	the	shaker	at	500rpm	
7. Supernatant	was	removed	and	the	plate	blotted	dry	
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8. 150μl	of	acylation	Buffer	was	added	 followed	by	25μl	of	acylation	 reagent	
and	incubated	for	15min	at	room	temperature	on	a	shaker	at	500rpm	
9. The	supernatant	was	removed	and	the	plate	blotted	dry	














6. Plates	were	washed	 using	 a	washer,	 3	 times	with	 300μl	 of	wash	 buffer	 in	
each	well	














(Y)	 axis	 and	 the	 corresponding	 concentration	 on	 the	 horizontal	 (X)	 axis	 on	 a	
logarithmic	axis.	The	concentrations	read	from	diluted	samples	were	multiplied	by	








project	 licence	 (Procedure	 Project	 Licence	 (PPL)	 –	 PC5F29685)	 approved	 by	 the	
Animal	welfare	and	Ethical	Review	Body	at	Queen	Mary	University	of	London,	and	
the	 UK	 Home	 Office,	 in	 accordance	 with	 the	 EU	 directive	 2010/63/EU	 on	 the	
protection	 of	 animals	 used	 for	 scientific	 purposes.	 The	 PPL	 includes	 all	 the	
experimental	 procedures	 required	 for	 the	 pre-clinical	 studies,	 including	 the	
induction	 of	 haemorrhage	 and	 traumatic	 injury,	 imaging	 procedures,	 dosing	
substances	and	blood	/	tissue	samplings.	This	PPL	was	renewed	on	December	2016	
and	has	been	granted	for	5	years	(to	December	2021).		
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2.4.1.	Mice	
Male	 C57BL/6	 wild-type	 mice	 weighing	 25	 –	 30	 grams	 were	 supplied	 by	 Charles	
River	 Laboratories	 (Margate,	 UK)	 and	 housed	 in	 accordance	 with	 the	 UK	 Home	




Isoflurane	 (Abbott	 Labs	 ltd,	 Berkshire,	 UK)	 in	 combination	 with	 100%	 medical	
oxygen	 was	 continuously	 delivered	 via	 nose	 cone	 for	 both	 induction	 and	




pressure	 transducer	was	 connected	 to	 the	 line	by	way	of	 a	 three-way	 connector.	
Pressure-controlled	 haemorrhage	 of	 arterial	 blood	 via	 the	 carotid	 catheter	 was	
conducted	 over	 10	minutes	 to	 achieve	 a	 target	MABP	 of	 60	 –	 70mmHg	 or	 30	 –	
40mmHg	 (depending	 upon	 the	 experimental	 group	 allocation).	 The	 target	 blood	
pressure	was	then	maintained	over	a	60-minute	period.	To	produce	truamtic	injury	
in	 the	 mice	 models	 bilateral	 hind	 limb	 fracture,	 laparotomy	 and	 rectus	 muscle	
crushing	were	carried	out.	Fractures	were	performed	using	a	closed,	manual	3-point	
bending	 technique.	 A	 2cm	 midline	 laparotomy	 was	 performed,	 with	 internal	
inspection	of	the	abdominal	viscera	in	order	to	exclude	inadvertent	iatrogenic	injury	
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and	 /	 or	 bleeding,	 followed	 by	 crushing	 of	 the	 rectus	 muscle	 and	 then	 the	
laparotomy	was	closed	using	5.0	monofilament	suture	material.	
2.4.4	Observation	periods	
After	 trauma-haemorrhage	 and	 resuscitation	 episodes,	 animals	 underwent	 a	 60-
minute	 observation	 period.	 During	 this	 time,	 core	 temperature	 was	 continuously	
monitored	 and	maintained	with	 the	 use	 of	 a	 heat	mat	 and	 lamps.	 Temperature,	










Conditions	 Mortality	 EM	 WB	 HFABP	
	
R43	 3h	 Sham	 N	 	 	 17.2	
R44	 3h	 Sham	 N	 X	 X	 14.64	
R68	 3h	 Sham	 	 	 X	 3.3	
R69	 3h	 Sham	 	 	 X	 3.4	
R76	 3h	 Sham	 N	 X	 X	 3.91	
R77	 3h	 Sham	 N	 X	 X	 38.26	
R90	 3h	 Sham	 N	 	 X	 3.33	
R91	 3h	 Sham	 N	 	 X	 3.48	
	 	 	 	 	 	 	
R41	 3h	 TH	 Y	 X	 	 334.28	
R42	 3h	 TH	 Y	 X	 	 (unable	to	bleed)	
R62	 3h	 TH	 N	 X	 X	 (unable	to	bleed)	
R64	 3h	 TH	 N	 X	 X	 432.60	
R78	 3h	 TH	 N	 	 X	 242.36	
R79	 3h	 TH	 N	 	 X	 193.57	
R81	 3h	 TH	 Y	 	 X	 76.43	
	 	 	 	 	 	 	
R65	 6h	 TH	 Y	 X	 X	 386.26	
R66	 6h	 TH	 N	 X	 X	 417.34	
R67	 6h	 TH	 N	 X	 X	 433.22	
	




Immunohistochemistry	 is	a	useful	 tool	 in	visualisation	expression	of	a	protein	and	
its	pattern	of	localisation	in	tissue.	Specific	antibodies	targeting	epitopes	of	interest	
are	 attached	 to	 chromogens	 to	 allow	 identification.	 The	 advent	 of	 fluorescence	
immunohistochemistry	 has	 made	 it	 possible	 to	 label	 multiple	 proteins	
simultaneously.		
Tissues	 must	 be	 preserved	 and	 fixed	 to	 maintain	 their	 structure	 and	 avoid	
degradation	 of	 proteins.	 Samples	 can	 be	 formalin	 fixed,	 fresh	 frozen	 or	 paraffin	
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2.5.3	Tissue	Handling	
Hearts	 were	 excised	 whilst	 animals	 were	 anaesthetised	 and	 immersed	 into	 4%	




temperature,	 90%	 ethanol	 two	 times	 for	 30	minutes	 each	 at	 room	 temperature,	
100%	 ethanol	 three	 times	 for	 30	minutes	 each	 at	 room	 temperature	 and	 xylene	
three	 times	 for	 20	 minutes	 each	 at	 room	 temperature.	 The	 tissue	 was	 then	
embedded	 in	 paraffin	 at	 58	 °C	 using	 an	 automated	 system.	 10	 μm	 thick	 sections	
were	cut	using	a	rotary	microtome	and	the	sections	were	floated	in	a	56	°C	water	
bath	and	mounted	onto	gelatin-coated	histological	slides.	The	slides	were	left	to	dry	





























pH	6.0	 pH	6.0	 pH	6.0	 pH	6.0	
pH	8.1	 pH	8.1	 pH	8.1	 pH	8.1	
pH	9.0	 pH	9.0	 pH	9.0	 pH	9.0	
2.5.7	Antigen	Retrieval	
The	 slides	 were	 placed	 in	 a	 plastic	 coupling	 jar	 with	 antigen	 unmasking	 solution	
(Vector	 Lab,	 Cat	 No.	 H-3300)	 into	 pre-heated	 saucepan	 of	 water	 pre-heated	 to			
90oC.	The	slides	were	heated	for	40	minutes,	and	then	placed	on	the	bench	for	30	
minutes	 to	 cool	 to	 room	 temperature.	 Slides	 were	 washed	 with	 0.1M	 PBS	 three	
times	for	10	minutes	each	time.	





normal	donkey	serum	diltuted	 in	PBS.	Following	this,	 the	slides	were	 incubated	 in	
primary	antibody	overnight.	The	slides	were	washed	3	times	for	15	minutes	each	in	
wash	 buffer	 and	 incubated	 in	 secondary	 antibody	 for	 2	 hours.	 The	 slides	 were	
mounted	with	Vectaschield	mounting	medium	with	DAPI	(Catalogue	No.	H-1200).		
2.5.9	Immunohistochemistry	Negative	Control	
Control	 experiments	 were	 carried	 out	 following	 protocol	 optimisation	 to	 gather	



















In	 molecular	 biology,	 western	 blotting	 is	 used	 to	 separate	 and	 identify	 proteins	
based	 on	 their	 molecular	 size.	 Unlike,	 ELISAs,	 more	 than	 one	 protein	 can	 be	
identified	 at	 a	 time	 by	 re-probing	 the	 same	membrane	 after	 stripping.	 However,	
unlike	 ELISAs,	 large	 number	 of	 samples	 can’t	 be	 run	 at	 once	 due	 to	 the	 time	
intensive	nature	of	 the	 technique.	 	Proteins	extracted	 from	tissue	or	cells	are	 run	
through	a	porous	polyacrylamide	gel	to	separate	them	by	size.	The	gels	are	loaded	
into	an	electrical	chamber	with	positively	and	negatively	charged	electrodes,	filled	




towards	 the	 anode	 and	 that	 leads	 it	 to	 the	membrane.	 The	membrane	 is	 probed	
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A	 portion	 of	 the	 heart	 was	 excised	 and	 weighed.	 A	 millilitre	 of	 RIPA	 buffer	 was	
added	to	every	0.1g	of	tissue.The	tissue	was	placed	on	glass	slide	in	RIPA	over	dry	
ice	and	gently	minced	using	a	fresh	razor	blade.	Then	the	minced	tissue	was	further	
disrupted	 in	 Dounce	 homogeniser	 with	 20	 strokes	 on	 ice.	The	 sample	 was	 then	






















Protein	 extraction	 from	 the	 hearts	 of	 the	 trauma	 haemorrhage	 models	 was	
quantified	using	a	Bradford	assay.	Known	amounts	of	bovine	serum	albumin	were	
loaded	alongside	protein	extraction	samples	from	the	trauma	models.	The	protein	
concentration	 of	 the	 samples	 were	 then	 extrapolated	 for	 those	 samples	 to	
determine	quantity	to	be	loaded	for	the	protein	gels.	The	calculated	amounts	were	
loaded	on	to	the	gel	were	then	transferred	to	a	blot	for	protein	expression	analysis.		






A	 silver	 stain	 was	 performed	 on	 a	 gel	 run	 with	 the	 amount	 calculated	 from	 the	










1. NuPAGE®	MOPS	 SDS	Running	Buffer	 (20X)-NP0001	was	made	up	 and	 tank	
filled	
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3. Gel	was	 placed	 between	 transfer	 paper	 and	 blotting	 paper	 as	 a	 sandwich	





Electron	 microscopy	 (EM)	 enables	 visualisation	 of	 tissue	 to	 0.2nm	 scale.	 This	
uniquely	 allows	 for	 the	 study	of	 ultrafine	 sub	 cellular	 structures	 in	 a	 great	 detail.	
Using	EM	proteins	of	interest	can	be	visualised	using	antibody	labelling	with	metal	
particles.	Mice	hearts	were	collected	and	immediately	fixed	in	Glutaraldehyde.	The	
samples	 were	 further	 fixed	 and	 processed	 for	 imaging	 by	 Dr	 Guilia	 Mastroianni,	
School	of	Biological	and	Chemical	Sciences,	QMUL.	
2.6.1	Cacodylate	buffer	0.1	M	pH	7.4	
Sodium	 cacodylate	 buffer	 [Na(CH3)2	 AsO2	 •	 3H2O]	 was	 introduced	 for	 EM	
applications	by	Sabatini	et	al.	in	1963	(114).	The	buffer	acts	to	maintain	a	pH	5.0–
7.4	 and	 in	 doing	 so	 negates	 the	 need	 to	 add	 additional	 phosphates	 to	 sample	





buffers	 (e.g.,	Tris).	 Its	 efficacy	 in	 fixation	 solutions	 may	 be	 a	 result	 of	 the	
metabolism-inhibiting	 effect	 of	 the	 arsenate	 rather	 than	 any	 special	 buffering	
capacity.	
2.6.2	Preparation	of	Buffered	2%	Glutaraldehyde		
A	 stock	 solution	 (A)	 of	 0.2	M	 Sodium	 Cacodylate	 was	made	 by	 dissolving	 4.48	 g	
sodium	cacodylate	in	100	mL	distilled	water	and	the	acid	stock	solution	of	0.2	M	HCl	
(B)	is	made	by	diluting	20ml	of	1M	HCl	with	80ml	of	distilled	water.	Preparation	of	
the	 buffer	 solution:	 mix	 100	 mL	 of	 stock	 A	 and	 5.4	 mL	 stock	 B	 followed	 by	 the	








1. in	 a	 disposable	 polythene	 beaker,	 40	 ml	 of	 araldite	 CY212,	 60	 ml	 of	
dodecenyl	succinic	anhydride,	2.0	ml	of	methyl	nadic	anhydride	and	1.0	ml	
of	benzyl	dimethylamine	were	combined	in	that	order.	






1. The	 tissue	was	dissected	and	 fixed	 in	2%	glutaraldehyde	 for	30	minutes	at	
room	temperature.	The	specimen	is	then	cut	into	small	1	mm3	and	stored	in	
fresh	fixative	in	4oC	for	1-7	days.	
2. The	 specimen	 was	 removed	 and	 washed	 for	 5	 minutes	 in	 the	 cacodylate	
buffer.	This	is	repeated	three	times.		
3. The	 specimens	 are	 removed	 from	 the	wash	 and	 incubated	 in	 1%	 osmium	
tetroxide	in	buffer	for	2	hours	at	4oC.	
4. Wash	in	distilled	water	3	x	5	minutes.	
5. Dehydration	 steps	 in	 25%	 acetone	 for	 15min,	 50%	 for	 15min,	 75%	 for	 15	
minutes	and	100%	twice	for	20	minutes.	













Statistical	 analysis	 was	 performed	 using	 IBM	 SPSS	 v22	 and	 GraphPad	 Prism	 was	




determined	 using	 Fisher’s	 exact	 test.	 Linear	 relationships	 were	 determined	 using	

























Several	 studies	have	 retrospectively	 investigated	 the	presence	of	 cardiac	 injury	 in	
trauma	 patients.	 The	 incidences	 of	 cardiac	 events	 and	 rise	 in	 cardiac	 biomarkers	






Cardiac	 disturbances	 after	 severe	 injury	 remain	 poorly	 characterized	 and	 the	
underlying	mechanisms	 remain	unclear/unknown.	Deaths	 from	 fulminant	multiple	
organ	 failure	 are	 often	 associated	with	 inadequate	 cardiac	 output	 and	 increasing	
requirements	 for	 inotropic	 support(116,117).	 	 Trauma	 patients	 have	 been	
repeatedly	 demonstrated	 been	 shown	 to	 develop	 rhythm	 disturbances	 and	 to	
suffer	 from	 ischemic	 cardiac	 events(26).	 This	 Trauma-Induced	 Secondary	 Cardiac	
Injury	 (TISCI)	 may	 contribute	 to	 the	 late	mortality	 and	 long-term	morbidity	 after	
trauma(118).	
	
It	 has	 been	 previously	 shown	 that	 patients	 who	 develop	 adverse	 cardiac	 events	
(ACEs)	have	elevations	of	plasma	cardiac	injury	biomarkers	very	early	in	their	clinical	
course(118).	 Heart-specific	 Fatty	 Acid	 Binding	 Protein	 (h-FABP)	 in	 particular	 was	
elevated	 immediately	on	admission	and	correlated	with	 the	development	of	ACEs	
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aim	 was	 to	 determine	 the	 incidence	 of	 ACEs	 and	 their	 effect	 on	 outcomes	 in	 a	
prospective	 cohort	 of	 trauma	 patients.	 Our	 second	 aim	 was	 to	 determine	 the	





TACID	was	conducted	at	Royal	London	Hospital,	a	 level	 I	 trauma	centre	 in	London	
from	September	2010	to	October	2012.	All	patients	who	were	above	the	age	of	16	
and	met	 the	 criteria	 for	 trauma	 team	activation	were	 screened	 for	 inclusion.	 The	
completion	of	the	study	was	marked	by	the	recruitment	of	300	patients	in	October	










the	 patients,	 82%	 had	 suffered	 a	 blunt	 injury,	 (82%)	 and	 with	 a	 median	 injury	





Adverse	 cardiac	 events	 were	 diagnosed	 using	 ECGs	 and	 defined	 as	 arrhythmias	
requiring	 intervention,	 ischaemic	 ECG	 changes	 such	 as	 T	 wave	 inversion,	 ST	
elevation	or	 depression	 and	new	onset	 bundle	 branch	block.	 The	diagnoses	were	
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		 All	patients	 No	ACE	 ACE	 Univariate	Analysis	
(p)	
No	Patients	(%)	 290	 252	(87%)	 38	(13%)	 <0.01	
Demographics	 		 		 		
Median	Age	(years)	 37	(16-91)	 37	(26-51%)	 47	(30-59)	 0.05	
<30	 102	(35%)	 91	(36%)	 11	(29%)	 		
31-45	 86	(30%)	 78	(31%)	 8	(21%)	 		
46-65	 71		(24%)	 61	(24%)	 10	(26%)	 		
66-80	 22	(8%)	 16		(6%)	 6	(16%)	 		
>81	 9	(3%)	 6	(2%)	 3	(8%)	 		
Male	 211	(73%)	 214	(85%)	 27	(71%)	 0.07	
Time	To	Sampling	 92	(71-	115)	 91	(73-	110)	 100	(76-	116)	 		
Injury	Characteristics	 	 	 		
Blunt	 237	(82)	 206	(82)	 31	(82)	 		
ISS	 17	(9-29)	 13	(9-25)	 30	(25-	43)	 <0.01	
Thoracic	AIS	 3	(0-3)	 1	(0-3)	 3	(2-4)	 <0.01	
H&N	AIS	 0	(0-3)	 0	(0-3)	 3	(0-4)	 0.01	
Admission	SBP	 126	(107-	146)	 130	(114-147)	 100	(67-125)	 <0.01	










in	 cardiac	 biomarkers.	 In	 addition	 the	 patients	 who	 developed	 ACE	 had	 more	
significant	 thoracic	 (AIS	score	3	vs.	1)	and	head	 injuries	 (AIS	0	vs	3).	Patients	with	
severe	thoracic	injury	were	more	likely	to	develop	an	adverse	cardiac	event	(42%	vs	







	 No	ACE	(n=252)	 ACE	(n=38)	 p	value	









Following	 recruitment,	 the	 patient’s	 past	 medical	 history	 and	 medication	 history	
were	obtained	from	the	patients	and	their	relatives.	These	were	confirmed	with	the	
medical	 history	 obtained	 from	 their	 general	 practitioner’s	 records.	Overall,	 7%	 of	
patients	had	a	pre-existing	diagnosis	of	 ischaemic	heart	disease.	Furthermore,	6%	








higher	 in	 the	 ACE	 group.	 	 Patients	 who	 developed	 adverse	 cardiac	 events	 were	
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more	 likely	 to	have	been	using	calcium	channel	blockers	and	statins	prior	 to	 their	
injury.	 This	 may	 be	 reflective	 of	 the	 increased	 incidence	 of	 hypertension	 and	






		 All	patients	 No	ACE	 ACE	 P	value	
No	Patients		 290	 252		 38		 	
Cardiovascular	disease	 		 		 		
IHD		 20	(7%)	 14	(6%)	 5	(13%)	 0.13	
Diabetes	 16	(6%)	 11	(4%)	 4	(11%)	 0.18	
Hypertension	 32	(11%)	 20	(8%)	 11	(29%)	 0.02	
Hypercholesterolemia	 24	(8%)	 14	(6%)	 9	(24%)		 0.02	
PVD	 1	(<1%)	 0		 1	(3%)	 0.15	
CVA	 3	(1%)	 3	(1%)	 0	 0.61	
Medication	
Anti-Platelet	 10	(3%)	 6	(2%)	 4	(11%)	 0.03	
Oral	Hypoglycaemic	 7		(2%)	 5	(2%)	 2	(5%)	 0.23	
Insulin	 3	(1%)	 1	(<1%)	 2	(5%)	 0.05	
Anticoagulants	 4	(1%)	 2	(1%)	 2	(5%)	 0.08	
Beta	blocker	 6	(2%)	 4	(2%)	 2	(5%)	 0.18	
ACEi	 16	(6%)	 12	(5%)	 4	(11%)	 0.14	
Ca	Channel	blocker	 9	(3%)	 4	(2%)	 5	(13%)	 0.03	
Diuretic	 8	(3%)	 6(2%)	 2	(5%)	 0.28	
Anti	anginal	 1	(<1%)	 1	(<1%)	 0	 0.87	
Nitrate	 3	(1%)	 3	(1%)	 0	 0.66	
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3.2.4	Electrocardiograms	
Electrocardiograms	 (ECGs)	 are	 a	 familiar	 and	 easily	 accessible	 examination	 tool,	
which	are	 in	fact	part	of	the	ATLS	guidelines	for	the	primary	survey	of	the	 injured	
patient.	 In	 routine	 practice	 however,	 due	 to	 the	 cumbersome	 nature	 of	 the	
equipment	 and	 the	 time	 critical	 environment	 they	 are	 often	 not	 completed.	
Patients	 included	 in	 the	 study	 were	 protocoled	 to	 have	 ECGs	 alongside	 blood	







one	 independent	 medical	 registrar	 (5	 years	 post	 qualification	 from	medical	 with	
postgraduate	exams	in	general	medicine).	
	 	












T	wave	inversion	 16	(6)	 19	(13)	 12	(11)	
RBBB	 9	(3)	 3	(2)	 3	(3)	
Sinus	Tachycardia	 8	(3)	 0	 1	(1)	
ST	changes	 7	(3)	 4	(3)	 2	(2)	
AF	 6	(2)	 1	(1)	 3	(3)	
LBBB	 4	(1)	 1	(1)	 0	
Prolonged	QT	 3	(1)	 1	(1)	 0	
LAD	 2	(1)	 1	(1)	 1	(1)	
1st	degree	heart	block	 2	(1)	 1	(1)	 1	(1)	
Ventricular	Ectopics	 2	(1)	 0	 2	(2)	
RAD	 1	(<1)	 3	(2)	 1	(1)	
Sinus	Arrhythmia	 0	 1	(1)	 0	










most	 common	ECG	 change	with	 a	prevalence	of	 6%.	 These	were	most	 frequently	
(63%)	seen	in	the	chest	leads.	Right	bundle	branch	block	(RBBB),	sinus	tachycardia	
and	 ST	 changes	 were	 also	 noted.	 Two	 of	 the	 nine	 patients	 who	 had	 RBBB	 had	
significant	thoracic	injury	with	a	thoracic	AIS	of	4	and	5	with	lung	injury.	The	other	
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all	 were	 new	 at	 24	 hours	 and	 transient.	 Two	 of	 the	 four	 patients	 had	 significant	
thoracic	injury	with	an	AIS	of	3	and	5.		
	
Sinus	 tachycardia,	 atrial	 fibrillation	 and	 Left	 BBB	 (LBBB)	 were	 also	 commonly	
transient	 changes	 at	 admission.	 The	 initial	 changes	 are	 likely	 to	 be	multifactorial	
and	 individual	 to	 the	 patient	 due	 to	 a	 combination	 of	 direct	 cardiac	 injury,	 rate	




adverse	 cardiac	 complications,	 15	 (5%)	 patients	 had	 ischaemic	 changes	 on	 their	
ECGs,	of	whom	6	(2%)	had	one	or	more	cardiac	risk	factors.	In	most	settings,	these	
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hours	 after	 injury	 were	 centrifuged	 and	 the	 plasma	 stored	 in	 -80oC	 prior	 to	
processing.	All	admissions	samples	from	admission	were	processed	for	troponin,	nt-
ProBNP	and	h-FABP.	The	Troponin	ELISA	completed	for	the	admission	samples	did	
not	 show	any	 differentiation	 between	 the	 samples.	 Following	 discussion	with	 the	
manufacturers,	 it	was	decided	not	 to	 further	proceed	with	 testing	of	 the	24	hour	
and	72	hour	samples.		
	
All	 but	 one	 patient	 had	 blood	 sampling	 on	 admission	with	 the	 bloods	 (table	 3.1)	
taken	at	a	median	sampling	time	of	92	minutes	overall,	91	minutes	 in	the	no	ACE	
group	 and	 100	 minutes	 in	 the	 ACE	 group.	 The	 difference	 in	 time	 was	 not	 of	
statistical	significance.	(Table	3.1).		81%	of	patients	had	blood	sampling	at	24	hours	
and	 62%	 at	 72	 hours.	 At	 72	 hours,	 patient	 refusal	 for	 blood	 sampling	 reduced	




four	 folds	higher	 than	 the	patients	who	did	not	develop	ACE.	At	24	hours	and	72	
hours	there	was	no	significant	difference.	 	The	median	plasma	levels	of	nt-ProBNP	
in	 the	 patients	 who	 did	 not	 develop	 ACE	was	marginally	 higher	 than	 the	 normal	
reference	value	provided	by	the	manufacturers.	It	was	also	higher	than	the	median	
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	 No	ACE	 ACE	 P	values	
h-FABP	(ng/ml)	
Admission	 15.2	(5.3-	50.7)	 62.0	(26.3	–	110.6)	 <0.001	
24	hour	 10.8	(3.5-	33.9)	 53.7	(8.2-	129.6)	 0.001	
72	hours	 4.4	(1.7-	9.6)	 8.9	(2.5-	54.5)	 0.04	
nt-ProBNP	(pmol/l)	
Admission	 400.6	(228.0	–	651.0)	 363.6	(0-473.5	 0.26	
24	hour	 422.8	(116.8-	994.9)	 461.5	(226.9-	1154.6)	 0.73	
72	hours	 246.3	(104.4-	447.6)	 231.3	(116.3-	573.7)	 0.73	
Troponin	





































Admission	 20.6	(6.2-	62.9)		 14.4	(5.4-	60.1)	 0.33	
24	hours	 12.9	(4.5-	53.7)	 18.4	(2.7-	37.9)	 0.44	
72	hours	 5.9	(1.9-	12.3)	 2.4	(0-12.0)	 0.06	
nt-ProBNP	
Admission	 380.9	(215.7-	614.7)	 435.2	(226.3-	706.4)	 0.55	
24	hours	 422.8	(117.0-	905.7)	 491.8	(137.4-	2169.5)	 0.19	
72	hours	 242.8	(108.7-	484.1)	 339.1	(95.7-	418.5)	 0.86	
Troponin	
Admission	 0	 0	 0.81	
Head	Injury	
HFABP		
Admission	 17.5	(6.2-	65.5)	 22.5	(5.1-	49.8)	 0.67	
24	hours	 15.6	(4.5-	48.4)	 8.8	(3.2-	27.3)	 0.13	
72	hours	 4.1	(1.7-	12.3)	 6.4	(2.0-	28.1)	 0.40	
nt-ProBNP	
Admission	 369.2	(208.7-	562.3)	 465.0	(318.8-	846.4)	 0.03	
24	hours	 448.0	(116.9-	1085.3)	 418.2	(181.5-	964.7)	 0.90	
72	hours	 231.4	(103.5-	417.0)	 325.1	(112.3-	541.3)	 0.41	
Troponin	
Admission	 0	 0	 0.16	
	
The	values	are	given	as	median	with	the	interquartile	ranges	in	parenthesis.		
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3.2.6	Echocardiograms	
Echocardiograms	 were	 requested	 through	 the	 hospital	 cardiac	 physiology	
department	at	 the	Royal	 London	on	all	 patients.	Due	 to	 the	 limited	availability	of	
the	 cardiac	 physiologist,	 only	 43	 (15%)	 patients	 had	 an	 echocardiogram,	 of	 those	
65%	 had	 complete	 data	 sets	 with	 good	 views.	 In	 the	 patients	 who	 had	
echocardiograms,	 19	 (44%)	 patients	 had	 an	 adverse	 cardiac	 event	 during	 their	























End	 diastolic	 and	 end	 systolic	 volumes	 can	 be	 used	 to	 approximate	 preload,	
afterload	 and	 contractility.	 The	 end	 diastolic	 volume	 is	 the	 volume	 of	 a	 filled	
vemtricle.	 Therefore	 a	 decrease	 in	 preload	 due	 to	 reduced	 venous	 return	 would	
lead	to	a	concurrent	decrease	in	the	end	diastolic	and	systolic	volume.	Changes	in	
ventricular	 contractility	 can	 also	 lead	 to	 changes	 in	 the	 ESV	 and	 EDV.	 Increase	 in	
heart	contractility	leads	to	a	reduction	in	ESV	and	a	concurrent	reduction	in	EDV.	
	
The	 left	 ventricular	 volumes	 are	 derived	 using	 the	 Teicholz	 formula	 to	 convert	
ventricular	 internal	 diameters	 during	 systole	 and	 diastole.	 The	 left	 ventricular	
internal	 diameter	 is	 calculated	 at	 end	 diastole	 and	 systole.	 The	 end	 systolic	
diameter	is	measured	at	the	end	of	the	t	wave	as	seen	on	ECG,	when	the	walls	are	
at	their	most	inward	position.		Similarly,	the	end	diastolic	measurement	is	taken	at	
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!"#$ !"#$%&'()*% !"#$%& = 72.4+ !"#$  ! !"#$!	
	
The	 end	 systolic	 volume	 in	 the	 ACE	 group	 (29ml)	 was	 lower	 than	 in	 the	 no	 ACE	
group	 (38.5ml)	but	not	of	 statistical	 significance.	This	 is	 also	 reflected	by	 the	EDV	
with	 lower	EDV	 in	 the	ACE	 (median	99ml-	 IQR	86-109)	group	compared	to	 the	no	
ACE	 (median	109ml-	 IQR	90-	119)	group.	This	may	be	due	 to	 the	 reduced	venous	


















its	maximal	volume	during	diastole,	as	follows:	!"#$%&'( !"#$%&'( = !"!"# − !"!"#!"!"#  ! 100	














diameter	is	calculated	as:	!"#$%&'(#) !"#$%&'(') = !"#$$ − !"#$%!"#$$  ! 100	
Fractional	shortening	seemed	to	have	an	upward	trend	with	adverse	cardiac	events,	
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The	E:A	ventricular	 filling	 ratio	 can	be	used	as	a	marker	of	diastolic	 function.	 The	


















patients	 developing	ACEs	 (37%)	 received	 Tranexamic	 acid	 compared	 to	 the	 group	
who	did	not	develop	ACEs	(15%).	Tranexamic	acid	administration	coincides	with	the	
initiation	of	 the	major	haemorrhage	protocol.	Therefore,	 this	may	be	 reflective	of	
the	increased	severity	of	injury	and	potentially	larger	number	of	patients	presenting	
with	active	bleeding.	The	higher	rates	of	inotropic	use,	as	well	as	diuretic	use,	in	the	
ACE	 cohort	 could	 be	 suggestive	 of	 a	 state	 of	 shock.	 As	 previously	 mentioned	 in	
Section	 3.2.4,	 15	 patients	 developed	 ischaemic	 changes,	 which	 would	 have	
warranted	 dual	 antiplatelet	 therapy	 in	 other	 patient	 groups.	 However,	 in	 the	
































ICU	 (95%	 vs	 47%,	 p<0.01)	 and	 on	 average	 required	 13	 days	 longer	 in	 ICU	 when	






Outcomes	 No	ACE	 ACE	 p	value	
ICU	admission	(%)	 47	 95	 <0.01	
ICU	Length	of	Stay	(Days)	 0	(0-2)	 13	(6-19)	 <0.01	
Total	Length	of	Stay	(Days)	 7	(2-15)	 28	(14-47)	 <0.01	
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3.2.10	Predicting	Adverse	Cardiac	Events	 	
H-FABP	was	 found	 to	be	associated	with	ACEs,	which	 in	 turn	was	associated	with	











Patients	 with	 plasma	 h-FABP	 levels	 above	 16.8	 ng/ml	 were	 assumed	 to	 have	
myocardial	 injury	 and	were	 defined	 as	 having	 trauma	 induced	 secondary	 cardiac	
injury	(TISCI).	Outcomes	of	these	patients	were	compared	to	those	not	developing	
TISCI.		






































Male	 113	(88%)	 125	(78%)	 0.19	
Cardiovascular	Disease	
IHD		 8	(6%)	 12	(7%)	 0.59	
Diabetes	 4	(3%)	 11	(7%)	 0.35	
Hypertension	 11	(9%)	 21	(13%)	 0.27	
Hypercholesterolemia	 8	(6%)	 16	(10%)	 0.49	
PVD	 0	 1	(<1%)	 0.58	
CVA	 1	(<1%)	 2	(1%)	 0.62	
Injury	Characteristics	
ISS	 9	(4-16)	 25	(13-34)		 <0.001	
Thoracic	AIS	 0	(0-1)	 3	(1-4)		 <0.001	
H&N	AIS	 0	(0-2)	 0	(0-4)	 0.45	
Admission	SBP	 137	(119-149)	 120	(97-139)	 <0.001	























H-FABP	(ng/ml)	 54.8	(35.9-	95.7)	 51.3	(25.0-	88.8)		 <0.01	
nt-ProBNP	(fmol/ml)	 342.0	(257.6-631.6)	 310.0	(254.9-522.1)	 0.66	
Troponin	I	(ng/ml)	 0	(0-0)	 0	(0-0)	 0.65	
Outcomes	
Inotrope	days	 0	(0-0)	 0	(0-3)	 	
ICU	Length	Of	Stay	 0	(0-0)	 1	(0-7)	 <0.01	
Total	Length	of	Stay	 4	(2-10)	 15	(7-37)	 <0.01	
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the	 previous	 smaller	 retrospective	 study	 presented	 by	 our	 group,	 but	 lower	 than	
that	 reported	 in	 other	 study	 populations	 (102,118,120).	 	 The	 commonest	 ECG	
changes	 was	 T	 wave	 inversion	 of	 which	 63%	 occurred	 in	 3	 or	 more	 chest	 leads,	
followed	 by	 supraventricular	 tachycardias	 predominated,	 but	 there	 was	 also	




existing	 cardiovascular	 diagnoses,	 and	 direct	 thoracic	 trauma	 appear	 to	 be	 risk	




Patients	 with	 evidence	 of	 TISCI	 had	 double	 the	 baseline	mortality	 while	 in	 those	
who	 went	 on	 to	 develop	 an	 ACE	 mortality	 was	 tripled.	 	 Although	 we	 primarily	
identified	 rhythm	disturbances,	 it	 is	not	 clear	how,	or	 if,	 these	contributed	 to	 the	
mode	 of	 death.	 	 We	 did	 not	 specifically	 measure	 cardiac	 function	 but	 inotropic	
support	 was	 similar	 across	 the	 groups.	 	 There	 is	 some	 experimental	 evidence	 to	
suggest	that	myocardial	damage	occurs	following	trauma	and	haemorrhagic	shock	
via	 a	 variety	 of	 postulated	 mechanisms	 (102,121,122).	 	 Human	 data	 on	 this	 is	




in	 trauma	patients	was	 studied.	 	On	 admission,	 h-FABP	was	 the	only	marker	 that	
was	 significantly	 raised,	 and	 56%	 of	 the	 patients	 had	 high	 levels	 of	 h-FABP	
suggestive	of	significant	myocardial	cell	damage	with	leakage	of	cytoplasmic	protein	
(123).	Furthermore,	the	patients	who	developed	ACE	also	had	persistently	higher	h-
FABP	 levels	 compared	 to	 the	 no	 ACE	 group.	 Although,	 h-FABP	 levels	 positively	
correlated	with	thoracic	injury	severity,	a	third	of	patients	with	myocardial	leak	had	
insignificant	chest	trauma.		Global	injury	severity	and	the	degree	of	shock	appear	to	
be	 strong	 factors	 in	 the	 development	 of	 TISCI.	 	 Putative	 mechanisms	 include	
ischemia,	 damage-induced	 inflammation	 or	 reperfusion	 injury	 (103,122,124,125).	
However,	the	specific	cardiac	pathology	and	underlying	mechanisms	have	not	been	
elucidated.	 	 Nevertheless,	 the	 presence	 of	 myocardial	 leak	 immediately	 on	
admission	 strongly	 correlated	 with	 adverse	 outcomes.	 	 H-FABP	 may	 be	 a	 useful	
early	biomarker	for	patient	risk	stratification.	In	an	inpatient	setting,	this	could	aid	





There	are	several	 limitations	 to	 this	study.	 	Although	prospectively	conducted,	we	
did	not	formally	measure	cardiac	output	or	other	aspects	of	cardiac	function	in	the	
cohort.	 	 Although,	 attempts	 were	 made	 to	 obtain	 echocardiographic	 data	 on	 all	
patients,	 deficiencies	 in	 service	 provision	 and	 a	 lack	 of	 availability	 cardiac	




are	more	reliable	 indicators	of	cardiac	function	(126).	 	Tissue	Doppler	 imaging	can	
be	 used	 to	measure	 the	 changes	 in	myocardial	 velocity	 over	 a	 cardiac	 cycle	with	
measurements	 taken	 at	 systole	 (S’),	 early	 diastolic	 relaxation	 (e’)	 and	 during	 late	
diastole	 (a’)	 (126).	 These	 show	 a	 linear	 correlation	 with	 LVEF	 but	 are	 also	 more	
sensitive	 markers	 of	 function	 as	 they	 are	 less	 volume	 dependent	 (127).	 	 Two-	
dimensional	 speckle	 tracking	 is	 an	 emerging	 technique	 for	 measuring	 cardiac	
contractility	through	analysis	of	the	migration	2	pixels	on	2-D	clips.	This	has	shown	
to	correlate	well	with	traditional	measures	of	systolic	and	diastolic	function	and	also	
more	 sensitive	at	 identifying	 reduced	 function.	 It	 is	 also	volume	 independent	and	
unlike	the	tissue	doppler	measurements	also	angle	independent	(128).		However,	in	
a	 centre	 with	 limited	 echocardiography	 facility,	 it	 was	 not	 possible	 to	 ascertain	
these	measurements.	No	other	functional	data	was	obtained	in	the	form	of	dynamic	







patient	 group	who	 develops	 cardiac	 injury	 is	 significantly	more	 injured	 and	more	
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shocked,	 therefore	 it	 may	 be	 inevitable	 that	 these	 patients	 go	 on	 to	 develop	 of	
secondary	cardiac	injury	as	part	of	the	systemic	inflammatory	insult	of	polytrauma,	
leading	 to	 multi	 organ	 failure	 and	 eventually	 leading	 to	 death.	 Late	 deaths	 in	
trauma	 are	 often	multifactorial,	 but	more	work	 needs	 to	 be	 done	 to	 explore	 the	
specific	contribution	TISCI	makes	to	morbidity	and	mortality	after	trauma.			
	

























injury,	 which	 induces	 with	 surge	 of	 catecholamines	 and	 unopposed	 sympathetic	
activation	 (130).	 Increased	 catecholamine	 levels	 have	 also	 been	 demonstrated	 in	






In	 traumatic	 brain	 injury	 patients	 studies	 have	 shown	 cardiac	 dysfunction,	 with	
prevalence	varying	from	8%	to	28%	in	different	studies	(133-135).	Beta-blockade	in	
TBI	has	been	shown	to	reduce	hospital	mortality	in	nine	observational	studies	(136).	




associated	 with	 endothelial	 dysfunction,	 coagulopathy	 and	 increased	 mortality	
(139)	 (140).	 A	 retrospective	 study	 noted	 a	 greater	 incidence	 of	 atrial	 fibrillation	
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associated	with	catecholamine	use	(141).	Although,	Arababi	et	al	also	demonstrated	




Although,	 the	 deleterious	 effects	 of	 catecholamines	 have	 been	 alluded	 to	 in	
polytrauma,	 their	 association	with	adverse	 cardiac	events	has	only	been	explored	
retrospectively.	 Study	 data	 collected	 during	 TACID	 demonstrated	 the	 elevation	 of	
cardiac	enzymes	following	traumatic	injury.	Release	of	these	enzymes	is	suggestive	
of	 cardiomyocyte	 death	 in	 this	 cohort.	 The	 aim	 of	 this	 chapter	 is	 to	 explore	 the	
contribution	 of	 catecholamines	 to	 cardiac	 injury	 as	 well	 as	 length	 of	 stay	 and	






in	 the	 group	 who	 developed	 ACE.	 Although,	 the	 distribution	 of	 the	 admission	
plasma	 dopamine	 levels	 is	 skewed,	 this	 was	 not	 significantly	 different.	 The	 ACE	
group	had	a	median	noradrenaline	concentration	of	2.03μg/ml,	twice	that	of	the	no	
ACE	 group	 at	 1.08	 μg/ml	 (normal	 reference	 0.19–0.23	 ng/mL).	 The	 adrenaline	
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concentration	on	admission	was	three	times	higher	at	0.67	μg/ml	compared	to	the	
no	 ACE	 group	 at	 0.26	 μg/ml	 (normal	 reference	 0.06–0.08	 ng/mL).	 Although	 the	
dopamine	concentration	on	admission	in	the	ACE	group	was	higher	0.0031	μg/ml	as	




of	 noradrenaline	 and	 dopamine	 but	 not	 adrenaline.	 	 The	 difference	 in	 plasma	
noradrenaline	concentration	became	much	more	apparent	with	a	concentration	of	
5.11	μg/ml	in	the	ACE	group	versus	0.88	μg/ml	in	the	no	ACE	group	-	representing	a	
six	 fold	 increase.	 	 The	 plasma	 adrenaline	 concentration	 at	 24	 hours	 is	 similar	
between	the	two	groups	with	0.095	μg/ml	 in	ACE	and	0.107	 in	the	no	ACE	group.	
Dopamine	concentration	only	demonstrates	a	difference	at	the	24-hour	time	point.	












of	ACE-	On	admission	 the	median	 serum	 levels	were	1.08	μg/ml	 (IQR:	0.49-2.0)	 in	








group	 vs.	 0.67	 μg/ml	 (IQR:	 0.30-	 2.44)	 in	 ACE	 (p=0.01).	 At	 24h-	 0.11	 μg/ml	 (IQR:	
0.46-0.21)	 in	 the	no	ACE	group	 vs.	 0.10	 (IQR:	0-0.22)	 in	ACE	 (p=0.6).	At	 72h-	0.81	
μg/ml	 (IQR:	 0.44-2.28)	 in	 the	no	ACE	group	 vs	 3.22	μg/ml	 (IQR:	 1.25-6.49)	 in	ACE	
(p<0.01).		





















and	 the	 severity	 of	 injury	 patients	 had	 sustained.	 	 An	 ISS	 of	 greater	 than	 15	was	
used	to	identify	severely	injured	patients.	The	severely	injured	patients	had	higher	
plasma	noradrenaline	levels	on	admission	compared	to	the	less	 injured	group	(1.2	
μg/ml	 vs.	 0.99μg/ml,	 p=0.01).	 This	 difference	 was	 sustained	 and	 becomes	 more	
marked	 at	 24	 hours;	 with	 plasma	 levels	 of	 1.7	 μg/ml	 in	 the	 more	 injured	 group	
almost	double	that	on	the	less	injured	group	at	0.9μg/ml	(p=0.01).	However,	at	72	
hours,	 the	 levels	 of	 noradrenaline	 had	 diminished	 in	 both	 groups	 and	 no	 evident	
difference	was	detectable	between	the	two	groups	(Figure	4.2).			
	
Plasma	 adrenaline	 was	 also	 raised	 on	 admission	 and	 the	 severely	 injured	 group	
displayed	more	than	double	the	circulating	levels	demonstrated	in	the	less	injured	
cohort	 (0.5	 μg/ml	 vs.	 0.2μg/ml	 respectively	 (p=0.001)).	 Serum	 adrenaline	 levels	
reduced	at	24	hours	in	both	groups	and	then	increased	at	72hrs	with	median	levels	
in	the	severely	 injured	patients	more	than	double	that	of	the	 less	 injured	patients	
(1.4	 μg/	 ml	 vs.	 	 0.6	 μg/ml	 (p=0.001)).	 The	 change	 at	 72	 hours	 is	 secondary	 to	
exogenous	adrenaline	administration	rather	that	a	physiological	response.	
	
Dopamine	 levels	 are	 also	 raised	 on	 admission	 and	 higher	 in	 the	 more	 severely	
injured	group	0.003	μg/ml,	whereas	the	median	in	the	less	injured	group	in	0	μg/ml	
(p=0.008).	The	dopamine	levels	rise	further	at	24	hours,	with	levels	in	the	severely	
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injured	 group,	 double	 that	 of	 the	 less	 injured	 group,	 0.014	μg/ml	 vs	 0.007	μg/ml	
(p<0.001).	
	
We	 then	 dichotomised	 patients	 according	 to	 the	 head	AIS	 (≤3	 vs.	 >3)	 in	 order	 to	
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Figure	 4.4	 Boxplot	 showing	 difference	 in	 noradrenaline	 levels	 in	 severely	 injured	







Figure	 4.5	 Boxplot	 showing	 difference	 in	 adrenaline	 levels	 in	 severely	 injured	

















as	 defined	by	head	and	neck	AIS>3	 -	On	admission	 the	median	 serum	 levels	were	
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HI	 (p=0.6).	 At	 72h-	 0.005	μg/ml	 (IQR:	 0-0.01)	 in	minor	HI	 vs	 0.003	μg/ml	 (IQR:	 0-
0.014)	in	severe	HI	(p=0.7).		





To	 further	 investigate	 the	 relationship	 between	 catecholamine	 levels	 and	 the	
development	 of	 cardiac	 injury,	 plasma	 catecholamine	 levels	 were	 divided	 into	







difference	 between	 the	 2nd	 and	 4th	 quartile	 of	 adrenaline	 concentration	 is	





all	 time	points,	 the	concentration	of	h-FABP	 is	statistically	significant	between	the	
2nd	 and	4th	 quartile.	 The	only	 statistical	 difference	 in	h-FABP	 levels	 in	 comparison	
with	Dopamine	concentration,	is	at	24	hours	between	the	1st	and	4th	Quartile.		
	 	








0-0.52	 0.52-1.11	 1.11-2.29	 >2.29	
Admission	 13.64	 13.44	 29.14	 27.87	
24	hours	 9.27	 4.95	 16.42	 32.19	





0-0.11	 0-0.11-0.030	 0.30-1.09	 >1.09	
Admission	 9.13	 13.04	 22.49	 43.23	
24	hours	 9.27	 4.95	 16.42	 32.19	





0-0.0001	 0.0001-0.002	 0.002-0.0107	 >0.0107	
Admission	 17.03	 10.59	 18.62	 59.37	
24	hours	 9.515	 4.27	 17.98	 131.4	
72	hours	 2.37	 2.31	 7.175	 38.29	
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Figure	 4.10	 Boxplot	 graph	 showing	 changes	 in	 h-
FABP	 levels	with	 increasing	 levels	of	noradrenaline.	
On	admission	(p=0.04*),	at	24	hours	(p=0.04)	and	at	
72	 hours	 (p=0.04)	 there	 is	 a	 significant	 difference	
between	the	2nd	and	4th	quartile.		
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Figure	 4.11	 Boxplot	 graph	 showing	 changes	 in	 h-
FABP	 levels	with	increasing	 levels	of	adrenaline.	On	
admission	 (p<0.001***),	at	24	hours	 (p=0.04*)	and	
at	 72	 hours	 (p=0.002**)	 there	 is	 a	 significant	
difference	 between	 the	 1st	 and	 4th	 quartile.	 On	
admission	 (p=0.008**)	 and	 at	 24	 hours	
(p<0.001***)	 there	 is	 also	 a	 significant	 difference	
between	2nd	and	4th	quartile.	










Further	 analysis	 was	 conducted	 by	 comparison	 of	 the	 plasma	 levels	 of	
catecholamines	 to	 the	presence	of	 TISCI,	 as	 defined	by	 plasma	h-FABP	of	 greater	
than	 16.8	 ng/ml,	 at	 the	 corresponding	 time	 points.	 	 On	 admission,	 the	 median	
plasma	noradrenaline	 level	of	1.4	μg/ml	was	1.5	times	higher	than	 in	the	no	TISCI	




median	 in	 the	 TISCI	 group	 of	 1.5	 μg/ml	 and	 the	median	 in	 no	 TISCI	 group	 of	 0.9	
μg/ml,	 this	 difference	 is	 not	 statistically	 significantly.	 The	 dopamine	 level	 at	 24	























Figure	 4.15	Boxplot	showing	difference	 in	dopamine	 levels	 in	TISCI	 -	On	admission	
the	median	 serum	 levels	 were	 0.001μg/ml	 (IQR:	 0-0.008)	 without	 TISCI	 group	 vs.	
median	0.003	μg/ml	(IQR:	0-	0.018)	in	TISCI	group	(p=0.2).	At	24h	median	was	0.01	
μg/ml	(IQR:	0.004-0.016)	without	TISCI	vs.	0.01	(IQR:	0.005-0.029)	with	TISCI	(p=0.1).	





Severe	 physiological	 stress	 leads	 to	 the	 initiation	 of	 the	 sympathetic	 system	 and	
leads	to	a	hyperadrenergic	state.	This	was	demonstrated	in	this	trauma	population.	
A	 plasma	 lactate	 level	 of	 greater	 than	 2mmol/l	 was	 taken	 as	 a	 surrogate	 for	
hypoperfusion	and	therefore	shock.	The	shocked	group	had	higher	levels	of	plasma	
noradrenaline	on	admission	(1.5	μg/ml	vs.	0.9	μg/ml,	p<	0.001).	Plasma	adrenaline	













Figure	 4.17	 Boxplot	 showing	 difference	 in	 adrenaline	 levels	 using	 lactate	 as	 a	
marker	of	shock	-	On	admission	the	median	serum	levels	were	0.22μg/ml	(IQR:	0.06-
0.69)	 in	 the	 not	 shocked	 group	 vs.	 0.60μg/ml	 (IQR:	 0.18-	 1.67)	 in	 the	 shocked	
(p<0.001***).	At	24h-	0.09μg/ml	(IQR:	0.05-0.22)	in	the	not	shocked	group	vs.	0.11	





















dobutamine,	 7%	 Dopexamine	 and	 4%	 milrinone.	 In	 the	 no	 ACE	 group,	 the	 only	
inotropes	 given	 was	 noradrenaline	 and	 dopexamine.	 In	 this	 group,	 36	 (12%)	
patients	 received	 inotropes	 and	 of	 those	 92	 %	 received	 noradrenaline	 only.	 The	
reasons	for	catecholamine	administration	were	not	collected.	However,	49%	of	the	













None	 of	 the	 patients	 included	 in	 this	 study	 received	 inotropes	 prior	 to	 baseline	
venepuncture;	 therefore	 the	 admission	 plasma	 catecholamines	 levels	 can	 be	
attributed	 to	 endogenous	 catecholamines	 production.	 The	 patients	 who	 require	
inotropic	 support	during	 their	 stay	have	higher	admission	 levels	of	noradrenaline,	
adrenaline	 and	 dopamine	 (Figure	 4.8).	 The	 high	 admission	 catecholamine	 levels	
may	 be	 a	 reflection	 of	 greater	 injury	 severity	 that	 consequentially	 leads	 organ	
dysfuction	 requiring	 inotropic	 support	 or	 it	 may	 be	 that	 the	 high	 levels	 of	




endogenous	 catecholamines.	 Catecholamine	 use	 is	 well	 established	 in	 the	













Figure	 4.19	 Boxplot	 showing	 difference	 in	 noradrenaline	 levels	 with	 inotrope	
administration	-	On	admission	the	median	serum	levels	were	1.01μg/ml	(IQR:	0.47-
1.97)	 without	 inotrope	 use	 vs.1.87μg/ml	 (IQR:	 0.92-	 3.68)	 with	 inotropes	





Figure	 4.20	 Boxplot	 showing	 difference	 in	 adrenaline	 levels	 with	 inotrope	
administration	-	On	admission	the	median	serum	levels	were	0.25μg/ml	(IQR:	0.10-
0.83)	 without	 inotrope	 use	 vs.	 0.78μg/ml	 (IQR:	 0.30-	 1.90)	 with	 inotropes	
(p<0.001***).	At	 24h-	 0.12μg/ml	 (IQR:	 0.05-0.23)	without	 inotropes	 vs.	 0.09	 (IQR:	





Figure	 4.21	 Boxplot	 showing	 difference	 in	 noradrenaline	 levels	 with	 inotrope	
administration	-	On	admission	the	median	serum	levels	were	0μg/ml	(IQR:	0-0.007)	










Admission	 noradrenaline	 levels	 in	 non-survivors	 were	 almost	 twice	 that	 seen	 in	
survivors,	1.74	μg/ml	vs	1.09	μg/ml.	This	difference	became	significantly	greater	at	
24	 hours	 with	 noradrenaline	 levels	 being	 nine	 times	 greater	 at	 8.08	 μg/ml	




















Figure	 4.23	 Plot	 showing	 difference	 in	 adrenaline	 levels	 in	 survivors	 and	 non-
survivors-	 On	 admission	 median	 levels	 were	 0.002μg/ml	 (IQR:	 0-0.009)	 without	







point	 in	 both	 survivors	 and	 non-survivors.	 Non-survivors	 had	 elevated	 plasma	
dopamine	 at	 all	 time	 points,	 with	 a	 significant	 difference	 seen	 at	 24h,	 with	 non	
survivors	 having	 three	 times	 higher	 plasma	 dopamine	 levels	 at	 0.03	 μg/ml	 when	




Figure	 4.24	 Plot	 showing	 difference	 in	 dopamine	 levels	 in	 survivors	 and	 non-
survivors-	 On	 admission	median	 dopamine	 levels	 were	 0.002μg/ml	 (IQR:	 0-0.009)	
without	 inotrope	use	vs.	0.003μg/ml	 (IQR:	0-	0.03)	with	 inotropes	 (p=0.1).	At	24h-	
0.010μg/ml	 (IQR:	 0.004-	 0.02)	 without	 inotropes	 vs.	 0.03	 (IQR:	 0.008-	 0.05)	 with	





Binomial	 logistic	 regression	was	 conducted	 including	 the	 variables	 listed	 in	 Table	
4.2.	 The	 model	 had	 a	 -2	 log	 likelihood	 of	 71.3	 (p<0.001),	 compared	 to	 the	 chi	
squared	 of	 106.1	 of	 the	 base	 model,	 therefore	 the	 inclusion	 of	 the	 variables	
improves	 the	 predictive	 value	 of	 the	 model.	 The	 pseudo	 R2	 value	 of	 0.50	
(Nagelkerke)	suggest	the	model	accounts	for	50%	of	the	variance	in	predicting	ACE.	








	 Chi-square	 df	 Sig.	
Step	1	 Step	 71.296	 15	 .000	
Block	 71.296	 15	 .000	

















Step	 Chi-square	 df	 Sig.	















Step	0	 ACE	 No	ACE	 202	 0	 100.0	
ACE	 36	 0	 .0	
Overall	%	 	 	 84.9	
Step	1	 ACE	 No	ACE	 177	 7	 96.2	
ACE	 16	 15	 48.4	










Sex	 .103	 .803	 .016	 .898	 1.108	 .230	 5.342	
Age	 .016	 .017	 .854	 .355	 1.016	 .982	 1.051	
ISS	 .016	 .029	 .320	 .571	 1.016	 .961	 1.075	
Thorax	AIS	 .361	 .192	 3.530	 .060	 1.435	 .985	 2.090	
H&N	AIS	 .321	 .182	 3.090	 .079	 1.378	 .964	 1.970	
IHD	 .763	 .968	 .621	 .431	 2.145	 .321	 14.311	
Diabetes	 -2.163	 1.247	 3.011	 .083	 .115	 .010	 1.324	
Hypertension	 2.131	 .765	 7.768	 .005	 8.424	 1.882	 37.698	
Hyperchol	 1.195	 .963	 1.539	 .215	 3.303	 .500	 21.813	
HR	 .006	 .010	 .367	 .545	 1.006	 .986	 1.027	
SBP	 -.016	 .007	 4.696	 .030	 .984	 .971	 .999	
Lactate	 .194	 .096	 4.094	 .043	 1.214	 1.006	 1.466	
Noradrenaline	 .007	 .013	 .273	 .601	 1.007	 .981	 1.033	
Adrenaline	 .041	 .164	 .061	 .804	 1.042	 .755	 1.437	
Dopamine	 3.470	 3.719	 .871	 .351	 32.142	 .022	 47068.853	














damage	 and	 coronary	 artery	 disease,	 which	 in	 turn	may	 lead	 to	 adverse	 cardiac	
events	with	 increased	physiological	 stress	 (143).	Hypertension	also	predisposes	 to	
the	development	of	atrial	fibrillation,	which	may	be	precipitated	by	the	injury	(144).	
An	alternative	explanation	may	be	that	patients	with	pre-existing	hypertension	and	
potentially	 left	 ventricular	 hypertrophy	 have	 poorer	 ability	 to	 autoregulate	 their	
coronary	 perfusion	 and	 even	 with	 minimal	 hypotension,	 there	 is	 a	 reduction	 in	




Within	 this	 model,	 thoracic	 injury	 does	 not	 significantly	 contribute	 to	 the	
development	 of	 ACE,	 therefore	 suggesting	 that	 it	 is	 not	 related	 to	 direct	 chest	
injury.	 Furthermore,	 this	 model	 also	 negates	 the	 contribution	 of	 catecholamine	
exposure	on	admission	to	the	development	of	adverse	cardiac	event.	On	examining	











Beta-adrenergic	 blockade	 has	 been	 identified	 as	 having	 potential	 benefits	 in	
critically	ill	trauma	patients	based	primarily	on	retrospective	cohort	studies	of	pre-
injury	 beta-blocker	 use.	 There	 are	 a	 number	 of	 putative	 mechanisms	 for	
catecholamine-induced	 cardiac	 injury,	 including	 ischemia	 due	 to	 poor	 diastolic	
filling,	or	directly-induced	calcium	overload	and	cardiomyocyte	necrosis	(95).			
	
In	 our	 study,	 admission	 levels	 of	 plasma	 adrenaline	 and	 noradrenaline	 were	
significantly	 higher	 in	 the	 patients	 who	 developed	 ACE.	 Furthermore,	 increasing	
levels	of	adrenaline	and	noradrenaline	were	associated	with	increasing	levels	of	h-
FABP	 on	 admission	 and	 24	 hours	 after	 injury.	 Despite	 this,	 we	 were	 unable	 to	
statistically	separate	any	differential	effects	of	adrenergic	stimulation	from	general	





catecholamine	 and	 therefore	 the	 plasma	 levels	 recorded	 on	 admission	 could	 be	
purely	attributed	to	endogenous	production.		
	
Measurement	 of	 catecholamines	 can	 be	 difficult	 to	 perform	 and	 analyse	 due	 to	
their	 short	 half-life.	 However,	 the	 biomarker	 analysis	 employed	 here	 was	
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determined	 to	be	 the	most	practical	way	of	measuring	 catecholamines	 in	 trauma	
patients.		
	
In	 summary,	 adrenaline	 and	 noradrenaline	 levels	were	 associated	with	 TISCI,	 the	
development	of	ACEs	and	subsequent	outcomes	including	mortality.		The	exact	role	
of	 catecholamines	 in	 the	genesis	of	TISCI	 remains	unclear	and	 further	 clinical	 and	
experimental	work	is	warranted.		There	exists	an	opportunity	to	improve	outcomes	
for	these	patients	with	patient	stratification	and	future	targeted	therapy.	Finally,	as	
mentioned,	 with	 this	 cohort	 study	 we	 were	 unable	 to	 specifically	 determine	



















The	 bleeding	 combined	 with	 tissue	 injury	 leads	 to	 a	 varying	 concoction	 of	
hypoperfusion,	 coagulopathy,	 catecholamine	 excess,	 release	 of	 DAMPs	 and	
immunological	 disarray	 which	 poses	 a	 huge	 risk	 to	 cellular	 processes(146).	 The	
myocardium	 with	 its	 usual	 high	 oxygen	 demands	 and	 a	 delicate	 blood	 supply	 is	
prone	 to	 damage	 during	 this	 catastrophic	 state.	 The	 sustained	 effort	 required	 to	
maintain	 perfusion	 in	 the	 face	 of	 haemorrhage,	 alongside	 a	multitude	 of	 noxious	
assaults,	 exerts	 pressure	 directly	 on	 the	 cardiomyocytes.	 Clinical	 studies	 have	
shown	the	cardiac	dysfunction	in	trauma	haemorrhage	can	be	evidenced	by	clinical	
events,	 ECG	 changes	 and	 an	 increase	 in	 circulating	 biomarkers(118,147).	 The	
cardiac	 dysfunction	 has	 been	 replicated	 in	 animal	 models	 with	 cytokines,	
inflammatory	 pathways	 and	 apoptosis	 implicated	 in	 the	 pathogenesis	 (148).	
However,	 in	 the	studies	 looking	at	apoptosis	and	cardiac	dysfunction,	surprisingly,	
there	was	no	increase	in	cardiac	biomarkers	(104).		
	








providing	 a	 murine	 model	 of	 TISCI.	 	 The	 release	 of	 cardiac	 proteins	 into	 the	
bloodstream	is	thought	to	be	due	to	disruption	of	the	cardiomyocte	cell	membrane	








augural	 of	 cell	 death.	 Myocardial	 death	 is	 not	 a	 reversible	 injury	 and	 will	 leave	




The	 work	 in	 this	 chapter	 aims	 to	 further	 investigate	 the	 effect	 of	 trauma	





Initially,	 through	 histopathological	 examination,	 the	 gross	 changes	 of	 the	
myocardium	in	TISCI	were	explored,	TEM	allowed	for	 further	visualization	of	 	 	 the	
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ultrastructure	structure	of	the	heart.	Subsequently,	western	blot	analysis	was	used	






The	 rise	 in	 serum	 cardiac	 proteins	 along	with	 their	 reflective	 depletion	 from	 the	
myocardial	 tissue	 indicates	 disruption	of	 cell	membrane	 integrity	 and	 subsequent	
cell	death.	In	myocardial	ischaemia,	necrosis	is	often	associated	with	the	ischaemic	
changes,	 therefore	 transmission	 electron	 microscopy	 (TEM)	 images	 of	 the	 heart	
were	 studied	 to	 identify	 ultrastructural	 changes	 in	 this	 TH	mice	model,	 that	may	
reveal	the	underlying	processes.		
	
The	 sham	 animals	 demonstrated	 normal	 myocardium	 with	 contracted	 myofibrils	
with	clearly	demonstrable	A	bands	and	Z	discs	(Figure	5.1).	The	nuclear	chromatin	is	
evenly	 distributed	 with	 a	 dense	 nucleoplasm	 with	 surrounding	 glycogen.	 The	
mitochondria	 are	 evenly	 distributed	 alongside	 the	 sacromere.	 	 The	mitochondria	







mice,	 showing	well-organised	myofibrils	 clearly	define	with	A	bands	 (green)	and	Z	
discs	(red),	M	band	(blue)	and	I	bands.	The	nucleus	(top	right)	shows	a	regular	intact	
nuclear	 envelope	 with	 evenly	 distributed	 chromatin	 in	 the	 nucleoplasm.	 The	
mitochondria	 (bottom	 right)	 are	 evenly	 distributed	 along	 the	 sarcoplasm	 with	
clearly	defined	cristae	and	even	electron	density	within	the	matrix.		
	
There	are	varying	degrees	of	 severity	 in	 the	changes	 seen	within	 the	heart	of	 the	
same	 animal.	 The	 organelles	 in	 different	 regions	 of	 the	 same	 heart	 demonstrate	
microscopic	changes	in	keeping	with	reversible	as	well	as	irreversible	cellular	injury.	
	
In	 areas	 with	 mild	 injury,	 the	 cardiac	 tissue	 maintains	 its	 similarity	 to	 the	 sham	
animals.	 These	 regions	 have	 well	 defined	 sarcomeres	 with	 linear	 myofibrils.	
However,	 the	 I	bands	are	more	prominent,	 indicative	of	 relaxation	of	 the	muscle,	





coronary	 artery	 ligation	 (149).	 In	 these	 less	 affected	 regions,	 the	 mitochondria	
remain	linearly	distributed	and	retain	normality	in	their	appearance.	The	cristae	are	




In	 the	 TH	 mice,	 33%	 of	 the	 mitochondria	 contain	 amorphous	 dense	 bodies	 in	
comparison	 to	 23%	 in	 the	 sham	 animals	 (p=0.006).	 Although,	 the	 loss	 of	 intra-
mitochondrial	 granularity	 has	 been	 described	 as	 one	 of	 the	 earliest	 changes	 in	













Rarefaction	 of	 the	 nucleoplasm,	 where	 there	 is	 loss	 of	 the	 chromatin	 as	
demonstrated	in	these	models,	is	often	seen	when	ischaemia	extends	greater	than	
15	 minutes	 (151).	 The	 nuclei	 in	 our	 TH	 animals	 also	 exhibit	 signs	 of	 irreversible	
structural	 changes,	 for	 example	 margination	 of	 chromatin,	 associated	 with	
surrounding	 oedema.	 Nuclei	 with	 chromatin	 condensation	 are	 contained	 in	 an	
organised	 fashion	within	 an	 oraganelle	 like	 structure,	which	 is	 neither	 in	 keeping	





with	 surrounding	 oedema	 (top	 left)	 and	 glycogen	 depletion	 (top	 right).	 There	 are	




In	 two	 in	 the	 longest	 surviving	 animals,	 the	 sarcomere	 partly	 retains	 its	
ultrastructure	with	the	definition	of	 the	myofibrils,	however	they	are	 fully	 relaxed	







are	 fragmented	 and	 irregular	 in	 shape,	 raising	 the	 possibility	 of	 mitochondrial	





Figure	 5.4:	 TH	model	myocardial	 tissue	 displays	widespread	 disorganistion	 of	 the	
myocardium	and	relaxation	of	the	sarcomere	demonstrating	prominent	M	&	I	bands	
(left)	and	poorly	circumscribed	mitochondria	distributed	in	a	disorderly	fashion.	The	
nuclei	 (top	 right)	 shows	 margination	 of	 chromatin	 and	 rarefaction	 of	 the	
nucleoplasm.	 There	 is	 widespread	 interstitial	 oedema	 (bottom	 right)	 with	
vacuolation	and	lipid	deposition.	
	






The	 TH	murine	model	 demonstrates	 cardiac	 injury	 through	 an	 increase	 in	 serum	
troponin	 and	 h-FABP	 (Methods	 2.3).	 Western	 blot	 analysis	 and	
immunohistochemistry	were	used	to	examine	 if	 these	 increases	 in	serum	proteins	




were	 used	 for	 immunohistochemistry	 analysis	 of	 protein	 expression.	 In	 the	 sham	
animals	 3	 points	 of	 interest	were	 analysed	 on	 4	 separate	 sections	 and	 in	 the	 TH	
models	 4-5	 points	 of	 interest	 were	 studied	 from	 2	 different	 sections.	 The	 single	
colour	 images	 were	 transformed	 to	 pixelated	 images	 using	 Image-J	 software	 to	
allow	 for	 approximate	 quantification	 of	 the	 proteins	 of	 interest	 and	 expression	
reported	as	mean	fluorescence.		
	
Protein	 extraction	 from	 the	 hearts	 of	 the	 trauma	 haemorrhage	 model	 was	
subjected	 SDS	 PAGE	 gel	 electrophoresis	 and	 blotted	 on	 PVDF	 membrane	 with	
specific	 antibodies	 for	 analyzing	 target	 protein	 expression	 analysis.	 A	 silver	 stain	
was	 then	 used	 to	 standardise	 proteins	 of	 interests.	 This	 was	 repeated	 for	 the	








On	 gross	 examination,	 there	 were	 no	 obvious	 changes	 in	 the	 pattern	 of	 cTnI	





compared	 to	 0.06	 in	 the	 sham	 animals.	 However,	 the	 difference	 was	 not	








Figure	 5.5:	 Troponin	 expression	 as	 demonstrated	 by	 IHC	 of	 paraffin	 embedded	
cardiac	 tissue.	 The	 sections	 were	 stained	 with	 primary	 mouse	 monoclonal	 cTnI	
antibody	and	conjugated	with	AF594.	Section	was	scanned	using	tiling	programme	




Figure	 5.6:	 Troponin	 expression	 derived	 from	 IHC	 of	 paraffin	 embedded	 cardiac	





























The	 decrease	 in	 cardiac	 structural	 protein	 expression	 as	 well	 as	 the	 associated	
ultrastructural	 changes	 indicate	 the	 onset	 of	 cell	 death	 (153).	 	 Traditionally,	 cell	
death	 has	 been	 defined	 into	 distinct	 processes	 such	 as	 necrosis,	 apoptosis,	
autophagy	 and	 oncosis.	 However,	 with	 newer	 insights,	 it	 is	 becoming	 more	
apparent	that	there	is	a	degree	of	crossover	between	the	pathways	(106).	Although,	
a	 rise	 in	 cardiac	 biomarkers	 is	 contributed	 to	 myocardial	 necrosis	 and	 cell	
membrane	 disruption,	 previous	 studies	 have	 associated	 cardiac	 dysfunction	 in	
trauma	with	 increased	myocardial	 apoptosis	 (35,104).	 The	diversity	 in	 the	 cellular	
changes	 seen	 on	 EM	with	 the	 absence	 of	 profound	 autolysis	 suggests	 that	 there	
may	 be	 many	 drivers	 of	 cell	 death	 in	 these	 models	 and	 not	 all	 dying	 cells	 are	





Caspase	 8	 is	 a	 downstream	 effector	 of	 the	 death	 receptor	 initiated	 cell	 death	
pathway.	 Upon	 western	 blotting	 using	 specific	 antibody	 and	 after	 adjusting	 the		
intensity	of	bands	expression	of	Caspase	8,	revealed	similar,	0.07	vs.	0.06	(p=0.20)	
levels	of	caspase	expression	in	the	samples	of	TH	and	the	sham	models.	However,	





Figure	 5.9:	 IHC	 of	 Caspase	 8	 expression	 IHC	 of	 paraffin	 embedded	 cardiac	 tissue	



















death	 proteins	 from	within	 the	mitochondria	 into	 the	 cytosol.	 Upon	 exposure	 to	
toxins	such	as	damaged	DNA	or	ROS,	PARP-1	receptors	are	activated	leading	to	the	
subsequent	activation	of	Bcl	pathways	which	in	turn	results	in	the	permeabilisation	
of	 the	 outer	 mitochondrial	 membrane	 (154).	 This	 permeabilisation	 leads	 to	 the	
cleavage	of	the	apoptosis	inducing	factor	(AIF)	to	its	death-inducing	active	form	into	
the	 cytosol,	 which	 then	 translocates	 to	 the	 nucleus	 where	 it	 leads	 to	 DNA	





To	 explore	 this,	 fresh	 murine	 hearts	 were	 homogenized	 and	 mitochondria	 were	
separated	 to	 look	 at	 the	 differential	 distribution	 of	 AIF	 and	 cytochrome	 C.	 In	
addition	to	the	whole	cell	expression	of	AIF	protein,	cells	were	fractionated	into	the	
cytosol	 and	 mitochondria	 portions	 in	 order	 to	 investigate	 alterations	 of	 AIF	
compartmentalisation	following	TH.		
	
Western	 blotting	 analysis	 demonstrated	 that	 the	 protein	 expression	 levels	 of	 AIF	




To	 further	 elucidate	 the	 distribution	 of	 proteins	 in	 the	 different	 sub	 cellular	
fractions	 obtained	 from	 heart	 tissue	 of	 TH	 models,	 the	 subcellular	 fractionation	
procedures	are	followed	and	differential	distribution	of	specific	proteins	of	interest,	
between	 the	 cytosol	 and	 mitochondria	 were	 investigated.	 Heart	 tissue	 was	
homogenized	 and	 then	 processed	 by	 differential	 centrifugation;	 at	 low	 speed	 to	
remove	 large	 organelles	 and	 debris	 and	 using	 a	 specific	mitochondrial	 extraction	
buffer	 (see	 methods	 section	 2.4.3)	 by	 high-speed	 centrifugation	 to	 isolate	 the	
mitochondria.	The	fractionated	samples	were	run	through	the	gels	and	probed	for	
AIF	and	positive	controls	were	used	to	confirm	mitochondrial	separation-	MTCO2	as	
a	 mitochondrial	 marker	 and	 GAPDH	 as	 a	 cytosolic	 marker.	 The	 change	 in	
distribution	 of	 AIF	 in	 the	 mitochondria	 versus	 the	 cytosol	 was	 assessed.	 The	
subcellular	 fractionation	procedure	 removes	 the	nuclei	 from	 the	 supernatant	 and	




Figure	 5.12:	 AIF	 expression	 as	 demonstrated	 by	 western	 blot	 analysis.	Mean	 optical	 density	 for	
sham	group	was	0.20	vs	0.17	for	the	TH	group	
	
In	 comparison	 to	 the	 sham	 animals,	 the	 TH	 animals	 show	 a	 reduction	 in	 AIF	
distribution	 in	the	mitochondria	to	supernatant	ratio.	The	mean	ratio	 in	the	sham	
models	is	1.5	in	comparison	to	0.4	in	the	TH	models,	however	this	is	not	statistically	
significant.	 This	 is	 suggestive	 that	 there	 is	 an	 increase	 in	 release	 of	 AIF	 in	 to	 the	
supernatant	where	the	trauma	becomes	lethal	 in	these	mice.	When	the	ratios	are	









Figure	 5.13:	 Comparison	 of	 mitochondrial	 vs	 Supernatant	 AIF	
compartmentalisation	 in	 sham	 and	 trauma	 haemorrhage	 murine	 hearts	 as	










Immunofluorescent	 microscopy	 was	 used	 to	 visualise	 the	 localisation	 of	 the	 cell	




with	 AF	 594	 (red)	 and	 AIF	 was	 an	 anti-rabbit	 primary	 antibody	 that	 was	 further	
labeled	with	an	anti-rabbit	secondary	antibody	with	AF	488	label	(green).		
	
AIF	 expression	 was	 examined	 through	 immunohistochemistry.	 In	 contrast	 to	 the	











On	 IHC	 analysis	 the	 nuclear	 localisation	 of	 AIF	 was	 more	 apparent	 in	 the	
resuscitated	 TH	 models	 when	 compared	 to	 the	 Sham	 models	 (Figure	 5.16).	 The	
image-j	 software	 was	 utilised	 to	 account	 for	 the	 degree	 of	 co-localisation	 of	 the	
proteins.	 Mitochondrial	 localisation	 was	 calculated	 to	 be	 0.05	 in	 the	 TH	 models	
compared	 to	 0.18	 in	 the	 sham,	 however	 this	 was	 not	 statistically	 significant.	



















The	 aim	 of	 this	 chapter	 of	work	was	 to	 further	 understand	 the	mechanisms	 that	
lead	 to	 ACE	 and	 the	 release	 of	 cardiac	 biomarkers.	 Using	 a	 mouse	 model	 of	 TH	





subcellular	 components	 such	 as	 the	 mitochondria	 in	 the	 murine	 trauma	
haemorrhage	models	 and	 potential	 drivers	 for	 the	 responses	 seen	 in	 our	 trauma	
patients.		
	
In	 the	 sham	 animals,	 EM	 demonstrated	 normal	 myocardial	 structure	 with	 well-
defined	 myofibrils,	 defined	 sarcoplasm	 and	 organized	 mitochondria	 throughout.	
Whereas	 in	 TH	mice	 this	 normal	 architecture	 and	 cellular	 organisation	 appeared	
disrupted.	 The	 most	 prominent	 feature	 in	 the	 myocardium	 of	 TH	 mice	 was	 the	
cellular	 oedema,	 varying	 from	 interspersed	 interstitial	 oedema	 to	 gross	 oedema	
leading	 to	 organelle	 swelling	 and	 myofibrillar	 disruption.	 Structural	 changes	 in	









There	 is	 a	 lot	 of	 variation	 in	 the	 significance	 of	 the	 amorphous	 dense	 bodies.	
Isolated	myocardial	cells	have	been	noted	to	develop	amorphous	dense	bodies	with	
just	 incubation	 at	 37oC	 without	 any	 change	 in	 their	 function,	 thought	 to	 be	
secondary	 to	 reorganisation	 of	 the	 structural	 proteins	 (155).	 However	 it	 has	 also	
been	associated	with	irreversible	injury	with	changes	in	the	mitochondria’s	ability	to	
utilise	 pyruvate	 and	 effectively	 respire	 (151,156,157).	 The	 intra-mitochondrial	
dense	 bodies	 occur	 following	 accumulation	 of	 precipitated	mitochondrial	 protein	
associated	 with	 calcium	 phosphate	 and	 influx	 of	 intracellular	 calcium,	 leading	 to	
ischaemia	(158).	However,	dense	bodies	have	been	noted	in	sudden	calcium	influx	
is	 also	 associated	 with	 hyperadrenergic	 states,	 (151).	 Dense	 body	 formation	 has	
also	been	demonstrated	following	anaesthesia	with	Propofol	in	murine	models	due	
to	the	reduced	coronary	flow	following	anaesthesia-induced	hypotension	(159).	The	
isoflurane	 similarly	 leads	 to	 hypotension,	 so	 its	 potential	 contribution	 to	 inducing	
dense	body	formation	should	be	taken	into	account.		
	
The	 TH	 mice	 demonstrated	 areas	 with	 severe	 injury,	 with	 widespread	
disorganisation	 of	 the	 myocardium	 and	 relaxed	 sarcomere	 in	 keeping	 with	
irreversible	 cell	 damage.	 These	 areas	 also	 demonstrated	 hollow	 mitochondrial	
matrix	with	 increased	electron	density.	Some	of	 these	changes	may	be	 in	keeping	
with	 reperfusion	 injury	 due	 to	 sustained	 hypoxia	 followed	 by	 reflow	 due	 to	
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crystalloid	 resuscitation.	 Cells	 that	 are	 irreversibly	 damaged	 with	 disruption	 to	
cellular	and	mitochondrial	membrane	integrity	have	been	shown	to	develop	further	
swelling	 and	 destruction	 with	 the	 presence	 of	 vacuolation	 as	 seen	 here	 (149).	
Reperfusion	of	the	cardiac	tissue	induces	calcium	influx	into	the	cells	perpetuating	




associated	 adverse	 cardiac	 outcomes	 (Li2015,	 bahloul,	 (135,160).	 This	 has	 been	
reflected	in	our	animal	models	with	TH	associated	with	rise	in	troponin	and	h-FABP.	
In	this	study,	using	the	TH	models	of	cardiac	injury,	we	were	able	to	establish	a	link	
between	 corresponding	 cellular	 changes	 and	 associated	 changes	 in	 protein	
expression.	 The	 western	 blots	 and	 immunohistochemistry	 studies	 demonstrated	
that	 these	 changes	 had	 reflective	 reduction	 in	 these	 cardiac	 proteins	 within	 the	
cardiac	 tissue.	 Cardiac	 troponin	 has	 been	 used	 in	 murine	 models	 of	 ischaemia	
induced	 by	 the	 ligation	 of	 coronary	 arteries	 (161).	 The	 induced	 infarct	 has	 been	
correlated	with	 a	 rise	 in	 troponin	 alongside	 a	 reduction	 in	 cardiac	 function	 (161).	
The	rise	in	troponin	has	also	been	demonstrated	in	models	following	isoproterenol	
induced	 cardiac	 toxicity	 (162).	 In	 these	 models,	 the	 rise	 in	 serum	 troponin	 was	
comparable	to	the	degree	of	coagulative	necrosis	seen	on	histology.	In	TH	models,	a	
few	 studies	 have	 explored	 the	 role	 of	 cell	 death	 in	 cardiac	 dysfunction	 in	 animal	
models(104,163).	 The	 pro-apoptotic	 proteins	 were	 seen	 to	 rise	 with	 cardiac	




noted	 that	 there	 is	 a	 rise	 in	 cardiac	proteins	 such	as	 troponin	and	h-FAPB.	 In	our	
study	we	have	demonstrated	 that	 this	 is	 associated	with	 changes	 in	 keeping	with	
ischaemia	 in	 the	myocardium.	 To	 distinguish	 the	 cell	 death	 pathways	 involved	 in	





However,	 AIF	 a	 cell	 death	 factor	 that	 activates	 upon	 mitochondrial	 stress	 is	
observed	 to	 translocate	 into	 nucleus	 from	 mitochondrion	 as	 observed	 in	 our	
subcellular	 fractionation	 studies	 by	western	 blotting	 and	 IHC	 analysis	 in	 TH	mice.	
Altogether	these	studies	report	a	rise	in	cardiac	biomarkers	such	as	CTnI	and	hFABP,	
that	 correlate	 with	 gross	 changes	 in	 mitochondrial	 ultra	 structures	 there	 by	
triggering	the	translocation	and	activation	of	death	 inducing	factors	such	as	AIF	 in	
these	TH	mice	models.	Mitochondrial	damage	has	been	noted	previously	in	trauma	






















previous	 retrospective	 studies	 (32).	 Unlike	 the	 temporal	 trend	 of	 h-FABP	 in	
pathologies	of	myocardial	stress	such	as	PE	where	it	rises	and	falls	within	24	hours,	
in	 TISCI,	 it	 remains	 raised	 throughout	 the	 first	 72	 hours	 (72).	 This	 raises	 the	
possibility	that	TISCI	occurs	over	days	and	the	ongoing	ischaemia	does	not	resolve	
with	 resuscitation.	 Patients	 who	 had	 higher	 levels	 of	 h-FABP	 on	 admission	 had	
worse	 clinical	 outcomes	 including	 increased	 mortality,	 longer	 length	 of	 hospital	





Furthermore,	 this	 study	 highlights	 an	 opportunity	 to	 identify	 patients	 with	
subclinical	 coronary	 artery	 disease.	 In	 patients	 who	 develop	 transient	 ischaemic	
changes	 with	 pre-existing	 cardiac	 risk	 factors,	 cardiology	 follow	 up	 should	 be	
considered	on	discharge	for	further	investigation	and	management.	
	
Interestingly,	 hypertension	was	 revealed	 as	 a	 significant	 contributor	 to	 TISCI,	 the	
reasons	 for	 this	may	 be	multifactorial.	 Hypertension	 not	 only	 induces	 endothelial	
damage	 but	 also	 leads	 to	 changes	 to	 the	 myocardium	 and	 predisposes	 to	 the	
development	 of	 arrhythmias	 (144).	 It	 may	 also	 be	 that	 hypertensive	 patients	
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accustomed	 to	 higher	 coronary	 perfusion	 pressures,	 even	 a	 small	 degree	 of	
hypotension	leads	to	a	greater	degree	of	cardiac	ischaemia	(165).	
	
This	 study	 further	 demonstrated	 the	 role	 of	 catecholamines	 in	 TISCI.	 Serum	
adrenaline	 and	 noradrenaline	 were	 higher	 in	 patients	 who	 developed	 ACE	 and	
predicted	inotropic	requirement.	Furthermore,	adrenaline	and	noradrenaline	levels	
had	an	incremental	effect	on	h-FABP	levels,	provoking	thoughts	of	effect.	However,	
on	 multivariate	 analysis,	 these	 were	 not	 calculated	 to	 be	 independent	 factors,	
potentially	due	to	their	co-linearity	with	degree	of	shock	and	injury	severity.		
	
Murine	models	 enabled	 further	 examination	 and	 validation	 of	 increase	 in	 cardiac	
injury	 associated	 biomarkers.	 The	 increase	 in	 serum	 h-FABP	 in	 these	 models	 is	
associated	with	reduction	in	its	tissue	concentration.	Furthermore	tissue	expression	
of	 troponin-I	 was	 also	 reduced.	 The	 most	 impressive	 finding	 was	 the	 degree	 of	
changes	 in	 ultra	 fine	 structures	 of	 sub	 cellular	 components	 such	 as	 myofibril	
organisation	 and	mitochondrial	 fission	 as	 analysed	 by	 electron	microscopy	 in	 the	
fixed	sections	of	cardiac	tissue.	There	is	definite	evidence	of	ischaemia	displayed	as	
widespread	oedema,	organelle	swelling	and	mitochondrial	changes.		This	alongside	





The	 Centre	 for	 Trauma	 Sciences	 at	 Blizard	 Institute	 Queen	 Mary	 University	 of	
London	 provides	 an	 excellent	 structure	 for	 translational	 research	 through	
collaborative	 efforts	 of	 clinicians	 from	 pre-hospital	 to	 rehabilitation	 and	 the	
research	 fellows.	 The	 assiduous	 data	 collection	 by	 research	 fellows	 who	 are	
clinicians	with	 a	dedicated	 interest	 in	 trauma	 sciences	 attests	 the	 integrity	 of	 the	






a	plethora	of	noxious	events	 including	but	not	 limited	 to	hypoperfusion,	bleeding	
diasthesis,	hyperadrenergic	stimuli	which	all	mediates	cellular	responses	leading	to	
inflammation,	multi-organ	 failure	 and	 death.	 To	 replicate	 this,	 is	 not	 a	 slight	 task	
and	 I	 was	 fortunate	 enough	 to	 be	 in	 a	 group	 with	 those	 extremely	 talented	 in	
animal	modeling.	Not	only	did	they	produce	trauma	haemorrhage	models	but	they	
also	 confirmed	 the	 presence	 of	 TISCI	 in	 the	models.	 Ease	 of	 access	 to	 the	 hearts	
from	the	TISCI	models	immensely	strengthened	the	work	produced	in	this	thesis	by	
facilitating	 the	exploration	 in	 to	 the	mechanisms	underpinning	cardiac	 injury.	This	
led	to	the	confirmation	of	cell	death	in	the	myocardium,	validating	cardiac	injury	as	
suggested	 by	 the	 increased	 blood	 levels	 of	 cardiac	 biomarkers	 and	 the	 novel	












difference	 in	 cardiac	 function	 in	 the	 TH	patients.	Due	 to	 the	 variability	 in	 time	of	
examination	and	patient	selection,	I	am	reluctant	to	put	this	forward	as	an	absolute	
finding.	Furthermore,	the	echocardiography	parameters	that	were	reported	within	
the	 completed	 studies	are	all	 sensitive	 to	 changes	 in	 volume,	although	 they	were	
completed	 following	 the	 initial	 resuscitative	 period	 where	 one	 may	 assume	 the	
patients	are	euvolaemic,	it	will	still	be	affected	by	changes	in	volume	distribution	as	
seen	 in	 SIRS	 following	 trauma.	 It	 would	 have	 been	 pertinent	 to	 examine	 more	
robust	 parameters	 such	 as	 tissue	 doppler	 index	 and	 global	 longitudinal	 strain.		
Further	 functional	 data	 could	 have	 also	 been	 collected	 using	 dynamic	 cardiac	
monitoring.	 For	 the	 duration	 of	 the	 TACID	 study,	 LiDCO	 availability	 was	 limited.	
Nonetheless,	 use	 of	 LiDCO	brings	 its	 own	 limitations,	with	 difficulty	 in	 calibration	
and	need	for	expertise	in	utilisation,	and	therefore	may	not	have	been	particularly	




Financial	 restraints	 necessitated	omission	 of	 troponin	measurement	 at	 24	 and	 72	
hours.	 The	 troponin	examination	would	have	 shed	 light	on	 the	 temporal	 trend	of	
TISCI	 in	addition	 to	h-FABP.	Furthermore,	 to	allow	 for	 seamless	 translation	of	 this	
work	 into	 clinical	practice,	measurements	 should	have	been	made	using	an	ultra-
sensitive	troponin	assay.	However,	on	a	small	scale	without	an	established	clinical	
indication,	 it	 was	 not	 possible	 to	 collaborate	 with	 the	 hospital	 lab.	 These	 assays	
would	 also	 have	 to	 been	 performed	 on	 dedicated	 machines	 which	 require	
outsourcing	 to	 the	 manufacturers	 and	 provide	 further	 budgetary	 demands.	 A	
weakness	 of	 the	 catecholamine	 ELISA	 is	 that	 exogenous	 and	 endogenous	
catecholamines	cannot	be	differentiated,	however,	to	answer	the	question	whether	
catecholamine	 exposure	 is	 associated	 with	 poorer	 outcomes,	 I	 felt	 an	
understanding	 of	 the	 temporal	 trend	 of	 catecholamine	 levels	 at	 24	 and	 72	 hours	
would	 be	 useful.	 I	 did	 not	 anticipate	 the	 magnitude	 of	 the	 contribution	 of	
exogenous	 catecholamines	 and	 potentially	 an	 insignificant	 contribution	 of	
endogenous	 catecholamines.	 Especially,	 as	 often	 catecholamine	 use	 beyond	 the	
initial	 resuscitative	 stage	 can	 be	 necessary	 and	 unavoidable,	 this	 is	 an	 unlikely	
management	 strategy	 that	 would	 be	 amenable	 to	 change	 to	 potentially	 improve	






80%	of	 their	 genes	with	humans,	 they	are	 still	 relatively	 genetically	distant.	Gene	
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expression	 studies	 in	 animal	 trauma	 models	 have	 shown	 low	 correlation	 with	
human	 genomic	 change	 (166).	 This	 can	 be	 overcome	 with	 correlation	 studies	 of	
genomic	changes	induced	by	trauma	in	mice	and	humans	with	subsequent	human	
cell	 studies	 to	 aid	 translation.	 The	 rodents’	 dissimilarity	 to	 humans	 make	 them	
insufficient	 as	 a	 stand	 alone	 model	 for	 development	 of	 novel	 therapeutic	
substances	 but	 one	 may	 argue	 sufficient	 for	 repurposing	 well	 established	
treatments.		
	
Although	 in	 combination,	 IHC	 and	 western	 blotting	 are	 useful	 for	 understanding	
pathologies,	 there	 are	 still	 many	 limitations.	 Western	 blotting	 provides	 an	
overarching	 measure	 of	 the	 protein	 expression	 whereas	 IHC	 enables	 study	 of	
protein	 distribution.	 In	 the	 data	 presented,	 the	 changes	 in	 expression	 did	 not	
correlate	between	the	two	methods,	for	example	the	total	AIF	expression.	Despite	a	
large	 number	 of	 repeated	measures,	 IHC	 still	 only	 allows	 investigation	 of	 a	 small	
region	of	the	whole	organ	whereas	western	blot	accounts	for	the	organ	as	a	whole,	




innovations	 have	 enabled	 conversion	 of	 these	 techniques	 in	 to	 quantitative	
methods	and	now,	this	is	well-established	practice.	However,	it	is	still	important	to	
correlate	 the	 numbers	 with	 blots	 and	 sections.	 Sophisticated	 software	 for	
calculating	 immunofluorescence	 and	 localisation	 index	 has	 made	 data	 easier	 to	
manage,	 interpret	 and	 present.	 However,	 a	 lot	 of	 information	 can	 be	 lost	 or	
		 176	
misinterpreted.	 There	 is	 still	 there	 no	 better	 substitute	 for	 careful	 visual	
interrogation.	
	
Although,	 the	 involvement	 of	 AIF	 in	 cardiac	 dysfunction	 and	 TH	 is	 novel	 and	
exciting,	this	needs	further	validation	with	gene	expression	analysis.	
6.4	Future	Work	
The	 evidence	 from	 the	 clinical	 studies	 highlights	 the	 prevalence	 of	 TISCI	 in	 our	
trauma	population.	Especially	 in	 light	of	 the	evidence	 regarding	 the	prevalence	of	
cardiovascular	 disease	 in	 out	 of	 hospital	 deaths,	 ACE	 in-hospital	 should	 instigate	
further	 investigation.	Surprisingly,	only	44%	of	 those	 that	developed	an	ACE	went	
on	to	have	an	echocardiogram,	this	was	mainly	due	to	limitations	of	expertise	in	the	
technique.	Echocardiograms	are	now	much	more	utilised	due	to	 increase	in	multi-
disciplinary	 training	as	well	 as	 the	 recognition	of	 their	utility	 in	prognostication	 in	
many	 disease	 processes.	 Future	work	 is	 needed	 to	 increase	 clinical	 awareness	 of	






well	 as	 the	 permeability	 transition	 pore	 of	 mitochondria	 (167).	 Recent	 human	
genomic	 studies	 of	 critically	 injured	 patients	 revealed	 the	 upregulation	 of	
mitochondrial	 stress	and	 respiration	genes	overall	and	 further	more,	upregulation	
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of	 cell	 death	 related	 genes	 in	multi-organ	 failure	 (168).	 The	 changes	 seen	 in	 the	
murine	 myocardium	 may	 potentially	 be	 reflective	 changes	 and	 intrinsic	 to	
multiorgan	 failure.	 Follow-up	 experiments	 replicated	 in	 stored	 lung	 and	 kidney	
tissues	from	the	same	models	could	aid	further	understanding.	Multiple	pre-clinical	
studies	 have	 highlighted	 melatonin	 as	 a	 potential	 candidate	 for	 alleviating	
mitochondrial	 swelling	 and	 permeability	 transition	 pore	 opening	 in	 ischaemia	
reperfusion,	 muscle	 injury	 and	 neurodegenerative	 diseases	 (169-171).	 Clinical	




explore(170).	 Further	 investigation	 in	 to	 therapeutic	 doses	 and	 effect	 on	 organ	
dysfunction	and	apoptosis	in	murine	studies	may	be	beneficial.	Additionally,	studies	
on	 the	 protein	 structure	 and	 interactions	 of	 AIF	 have	 suggested	 both	 hsp70	 and	
XIAP	as	potential	targets	for	mitigating	apoptosis.		However,	therapeutic	molecules	
to	 potentiate	 their	 anti-apoptotic	 properties	 are	 still	 being	 developed	 (167).	
Therefore	 characterisation	 of	 various	 proteins	 that	 regulate	 apoptotic	 signaling	
cascades	 could	 insight	 clues	 to	 disease	 mechanisms	 in	 these	 TH	 mice	 models.	
Moreover,	 ultra	 structural	 changes	 in	mitochondria	 and	 nuclear	 chromatin	might	
possibly	indicate	changes	in	genome	architecture	and	assembly.	This	could	lead	to	
increase	 in	DNA	damage	 response	 and	 changes	 in	 transcriptional	 state	 of	 cells	 in	
these	mice.	 Further	 exploration	 to	 understand	 the	 basic	 biology	 underlying	 these	
mice	 models	 could	 provide	 insight	 into	 disease	 mechanisms	 and	 therefore	 open	
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 Telephone: 01223 597597  
Facsimile: 01223 597645 
03 September 2010 
 
Professor Karim Brohi 
Consultant in Trauma, Vascular & Critical Care Surgery 
Royal London Hospital 
Trauma Clinical Academic Unit 
Royal London Hospital 
Whitechapel Road, London 
E1 1BB 
 
Dear Professor Brohi 
 
Study Title: Trauma Associated Cardiac Injury, Dysfunction & Death 
(TACIDD) 
REC reference number: 10/H0306/47 
 
Thank you for your letter of 23 August 2010, responding to the Committee’s 
request for further information on the above research and submitting revised 
documentation. 
 
The further information has been considered on behalf of the Committee by the 
Chair.  
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion 
for the above research on the basis described in the application form, protocol 
and supporting documentation as revised, subject to the conditions specified 
below. 
 
Mental Capacity Act 2005 
 
I confirm that the committee has approved this research project for the purposes 
of the Mental Capacity Act 2005. The committee is satisfied that the requirements 
of section 31 of the Act will be met in relation to research carried out as part of 
this project on, or in relation to, a person who lacks capacity to consent to taking 
part in the project.  
 
Ethical review of research sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to 
the start of the study (see “Conditions of the favourable opinion” below). 
The Committee has not yet been notified of the outcome of any site-specific 








favourable opinion does not therefore apply to any non-NHS site at present. I will 
write to you again as soon as one Research Ethics Committee has notified the 
outcome of a SSA. In the meantime no study procedures should be initiated at 
non-NHS sites. 
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the 
start of the study. 
 
Management permission or approval must be obtained from each host 
organisation prior to the start of the study at the site concerned. 
 
For NHS research sites only, management permission for research (“R&D 
approval”) should be obtained from the relevant care organisation(s) in 
accordance with NHS research governance arrangements.  Guidance on 
applying for NHS permission for research is available in the Integrated Research 
Application System or at http://www.rdforum.nhs.uk. 
 
It is the responsibility of the sponsor to ensure that all the conditions are 
complied with before the start of the study or its initiation at a particular 
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appointed representative consent form  
1.2  30 July 2010  
 Evidence of insurance or indemnity: Barts & The London   01 June 2010  
  
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements 
for Research Ethics Committees (July 2001) and complies fully with the Standard 











After ethical review 
 
Now that you have completed the application process please visit the National 
Research Ethics Service website > After Review 
 
You are invited to give your view of the service that you have received from the 
National Research Ethics Service and the application procedure.  If you wish to 
make your views known please use the feedback form available on the website. 
 
The attached document “After ethical review – guidance for researchers” gives 
detailed guidance on reporting requirements for studies with a favourable opinion, 
including: 
 
1.   Notifying substantial amendments 
2.   Adding new sites and investigators 
3.   Progress and safety reports 
4.   Notifying the end of the study 
 
The NRES website also provides guidance on these topics, which is updated in 
the light of changes in reporting requirements or procedures. 
 
We would also like to inform you that we consult regularly with stakeholders to 
improve our service. If you would like to join our Reference Group please email 
referencegroup@nres.npsa.nhs.uk.  
 












Enclosures: “After ethical review – guidance for researchers”  
 
Copy to: Mr Gerry Leonard 
R&D Department 
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Appendix III 
Patient information sheet   
 
DIRECTORATE OF SURGERY AND ANAESTHESIA 
ROYAL LONDON HOSPITAL, WHITECHAPEL, LONDON E1 1BB 
 
Information Sheet A – Subject 
Version 1.2, 30/07/2010  
 
Cambridgeshire 3 Research Ethics Committee 
REC number:  10/H0306/47 
 
Title:  Trauma Associated Cardiac Injury and Dysfunction (TACID A)  
Principal Investigator: Mr. Karim Brohi, FRCS FRCA    
 
Date: ___/___/_____ 
Subject Name: _____________.   NHS Ref: ___________ Study Ref: ________ 
 
Introduction 
You are being invited to take part in a research study. This research will help us 
to improve the care of patients who suffer severe injuries in the future. Before you 
decide, it is important for you to understand why the research is being done and 
what it will involve.  Please take time to read the following information carefully. 
Talk to others about the study if you wish. Ask us if there is anything that is not 
clear or if you would like more information. Take time to decide whether or not 
you wish to take part. 
Why is this research being carried out? 
Trauma (serious injury) is a serious health problem worldwide. Once discharged 
home, trauma patients are more likely to be limited in their daily activities 
compared to similar people who have not been injured.  Injury, shock and blood 
loss may damage the heart, which might lead to the above. If this is the case, the 
extent and frequency of heart damage and dysfunction in trauma patients is not 
known, and we hope that this research will help us to determine if, who and how 
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Coupled with this, we want to find out what happens to trauma patients who 
already have diseased hearts before injury, and compare their outcomes to 
similar patients with normal healthy hearts.  
Why have I been chosen? 
On ___ - ___ - ______ (date), you were injured and admitted to the Royal 
London Hospital.  At the time, you were unable to give informed consent.  When 
you arrived in the emergency department, a full trauma team of doctors and 
nurses attended to you.  The trauma team leader, who is not part of this research 
study, gave consent as your representative.  As part of the immediate 
management, a heart trace (ECG) was performed and blood taken and sent to 
the laboratory for analysis.  A small amount of extra blood (approximately 1 
teaspoonful) was drawn and saved for research purposes.  We are now asking 
for your consent to allow us to use the samples we have collected and to 
continue to participate in the study, since all the procedures have not yet been 
completed. 
Do I have to take part? 
No, participation is completely voluntary.  It is up to you to decide whether or not 
to take part.  If you do, you will be given this information sheet to keep and be 
asked to sign a consent form.  You are still free to withdraw at any time and 
without giving a reason.  A decision to withdraw at any time, or a decision not to 
take part, will not affect the standard of care you receive. 
What will happen to me if I take part? 
If you agree to continue with the study the following will happen: 
1. We will store and process the samples we have already collected. 
2. We will continue to collect blood samples and heart traces (ECGs) until the 
3rd day in hospital.  3 of each in total.  Each blood sample is equivalent to 1 
teaspoonful, and the total amount of blood drawn over 3 days is less than 1 
fluid ounce.  Wherever possible we will draw the blood out of a line already in 
a blood vessel, or coincide the blood draw with tests required for your care, 
in order to minimise any discomfort from the procedure. 
3. We will perform an echocardiogram (Echo) during your admission, at a time 
that is convenient to you and medically appropriate.  An Echo is an 
ultrasound of the heart, and will give us information on the appearance and 
function of your heart.  
4. This will take approximately 30 minutes, and is undertaking by placing some 
jelly on your chest followed by a probe that produces the images.  It is very 
safe, but if the chest wall is injured, can be a little uncomfortable.   
		 198	
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We will give you painkillers if this is the case, which will allow the test to be 
performed pain free. 
5. When you go home, or at 30 days after your accident, we will ask you to fill 
in a questionnaire designed to assess your health perception.  It is easy to 
complete and should take no more than 10 minutes.   
6. We also need permission to access your health records, so that we can 
assess your health one year after your accident.  This information is 
confidential, and will only be seen by the research team.  It will only be used 
for the purpose described above in this study. 
What do I have to do? 
If you agree to continue with the study the following will happen: 
1.  We will collect ___ (number) of further blood samples and ___ ECGS from 
you, on ___________(date/times) 
2.  We will perform an Echo at a convenient time to you during the course of your 
admission. 
What are the possible disadvantages and risks of taking part in the study? 
There are no long-term risks to you from participating in this study.  The specific 
risks associated with each investigation are as follows: 
1. Blood samples: 
The risks of drawing blood include temporary discomfort from the needle stick 
and bruising. 
2. Echocardiogram: 
There is no risk to your health from an Echo, however, if you have chest wall 
injuries, you may find the procedure a little uncomfortable.  We will give you 
painkillers if this is the case and only proceed when you are happy for us to do 
so. 
What are the possible benefits of taking part in the study? 
In the event that we detect an abnormality with your heart, we will refer you with 
your consent to a specialist in order to ensure you get appropriate care and 
follow up.  In addition, we hope that the information we get will help to improve 
the care of trauma patients in the future. 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed.  The detailed information on 









Will my taking part in the study be kept confidential? 
Yes.  We will follow ethical and legal practice and all information about you will be 
handled in confidence.  The details are included in Part 2. 
This Completes Part I. 
If the information in Part 1 has satisfied you and you are considering continuing in 
the study, please read the additional information in Part 2 before making any 
decision. 
 












What will happen if I don’t want to carry on with the study? 
If you decide, at any time, to withdraw from the study all study procedures will be 
stopped immediately.  Any information and samples that have already been 
collected will be processed as part of the study unless you wish to have your 
samples withdrawn from the study, in which case we will destroy them.  Your 
decision will in no way result in a change in the type or quality of care you 
subsequently receive. 
What if I am not happy about the study? 
We will only make very minor changes to the way we look after you.  It is 
extremely unlikely that this small change to normal practice would cause any 
problems.  However, if taking part in this study harms you, there is no special 
compensation arrangement.  If you are harmed due to someone’s negligence, 
then you may have grounds for legal action but you may have to pay your legal 
costs. Regardless of this, if you wish to complain or have any concerns about any 
aspect of the way you have been approached or treated during the course of this 
study, the normal National Health Service complaints mechanisms should be 
available to you.  Please contact Patient Advisory Liaison Service (PALS) if you 
have any concerns regarding the care you have received, or as an initial point of 
contact if you have a complaint.  Please telephone 020 7377 6335, minicom 020 
7943 1350, or email pals@bartsandthelondon.nhs.uk.  You can also visit PALS 
by asking at any hospital reception. 
Will my taking part in the study be kept confidential? 
All information that is collected about you during the course of the research will 
be kept strictly confidential and will be stored securely in coded form.  If you 
consent to take part in the research, the people conducting the study will abide 
by the Data Protection Act 1998, and the rights you have under this Act.  Only 
authorised personnel such as researchers and research auditors will have 
access to the data.  Any subsequent use of the samples will have to be 
performed with approval from a research ethics committee, otherwise the 
samples will be destroyed.  
What will happen to the samples that I give? 
We would like your permission to store your blood samples for further research.   
Any further use of your samples outside of this research study will have to be 
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What will happen to the results of the research study? 
We hope to publish the results in a scientific journal.  It will not be possible to 
identify any individual who has taken part from this scientific report.  Copies of 
the report will be available on request. 
Who has reviewed the study?  
All research in the NHS is looked at by independent group of people, called a 
Research Ethics Committee to protect your safety, rights, wellbeing and dignity. 
This study has been reviewed and given ethical approval by the Cambridgeshire 
3 Research Ethics Committee. 
Who can I contact for further information? 
1. If you require further information about the study, please contact the 
TACID study offices via the Trauma Surgery secretary at 020 7377 7000, 
x7695 or email: Henry.De’Ath@bartsandthelondon.nhs.uk 
2. If you require impartial, local advice, please contact the Patient Advice 
and Liaison Service, telephone: 020 7943 1335 or e-mail: 
pals@bartsandthelondon.nhs.uk 
Thank you for taking the time to read this sheet.  













Information for Consultee   
 
DIRECTORATE OF SURGERY AND ANAESTHESIA 
ROYAL LONDON HOSPITAL, WHITECHAPEL, LONDON E1 1BB 
 
Information Sheet C - Consultee 
Version 1.2, 30.07.2010  
 
Cambridgeshire 3 Research Ethics Committee 
REC number: 10/H0306/47 
 
Title: Trauma Associated Cardiac Injury and Dysfunction (TACID A) 
Principal Investigator: Mr. Karim Brohi, FRCS FRCA    
 
Date: ___/___/_____ 
Subject Name: _____________.   NHS Ref: ___________ Study Ref: ________ 
 
Introduction 
We feel your relative/friend is unable to decide for himself/herself whether to 
participate in this research.  To help decide if he/she should join the study, we 
would like to ask your opinion whether or not they would want to be involved.  We 
would ask you to consider what you know of their wishes and feelings, and to 
consider their interests.  Please let us know of any advance decisions they may 
make about participating in research.  These should take precedence.  If you are 
unsure about the role of consultee you may seek independent advice.  We will 
understand if you do not want to take on this responsibility.  The following 
information is the same as would have been provided to your relative/friend. 
Why is this research being carried out? 
Trauma (serious injury) is a serious health problem worldwide.  Once discharged 
home, trauma patients are more likely to be limited in their daily activities 
compared to similar people who have not been injured.  Injury, shock and blood 
loss may damage the heart, which might lead to the above. If this is the case, the 
extent and frequency of heart damage and dysfunction in trauma patients is not 
known, and we hope that this research will help us to determine if, who and how 






Coupled with this, we want to find out what happens to trauma patients who 
already have diseased hearts before injury, and compare their outcomes to 
similar patients with normal healthy hearts.  
Why have they been chosen? 
On ___ - ___ - ______ (Greenland P), your relative or significant other was 
injured and admitted to the Royal London Hospital.  At the time, they were unable 
to give informed consent.  When they arrived in the emergency department, a full 
trauma team of doctors and nurses attended to them.  The trauma team leader, 
who is not part of this research study, gave consent as their representative.  As 
part of the immediate management, a heart trace (ECG) was performed and 
blood taken and sent to the laboratory for analysis.  A small amount of extra 
blood (approximately 1 teaspoonful) was drawn and saved for research 
purposes.  We are now asking for your consent to allow us to use the samples 
we have collected and to allow their continued participation in the study, since all 
the procedures have not yet been completed. 
Do I have to agree? 
No, participation is completely voluntary.  It is up to you to decide whether or not 
your relative/significant other should take part.  If you do, you will be given this 
information sheet to keep and be asked to sign a declaration form.  You are still 
free to withdraw at any time and without giving a reason.  A decision to withdraw 
at any time, or a decision not to take part, will not affect the standard of care your 
relative/significant other receives. 
What will happen to them if they take part? 
1. If you agree to continue with the study the following will happen: 
2. We will store and process the samples we have already collected. 
3. We will continue to collect blood samples and heart traces (ECGs) until the 
3rd day in hospital. 3 of each in total.  Each blood sample is equivalent to 1 
teaspoonful, and the total amount of blood drawn over 3 days is less than 1 
fluid ounce.  Wherever possible we will draw the blood out of a line already in 
a blood vessel, or coincide the blood draw with tests required for their care, 
in order to minimise any discomfort from the procedure. 
4. We will perform an echocardiogram (Echo) during the admission, at a time 
that is convenient and medically appropriate.  An Echo is an ultrasound of 
the heart, and will give us information on the appearance and function of the 
heart.  This will take approximately 30 minutes, and is undertaking by placing 
some jelly on the patient’s chest followed by a probe that produces the 
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It is very safe, but if the chest wall is injured, can be a little uncomfortable.  
We will give painkillers if this is the case, which will allow the test to be 
performed pain free. 
5. When home, or at 30 days after the accident, we will ask your relative or 
significant other to fill in a questionnaire designed to assess their health 
perception.  It is easy to complete and should take no more than 10 minutes.  
6. We also need permission to access their health records, so that we can 
assess their health one year after your accident.  This information is 
confidential, and will only be seen by the research team.  It will only be used 
for the purpose described above in this study. 
What do they have to do? 
If you agree to continue with the study the following will happen: 
1.  We will collect ___ (number) of further blood samples and ___ ECGS from 
them, on_________(date/times) 
2.  We will perform an Echo at a convenient time to you during the course of 
his/her admission. 
What are the possible disadvantages and risks of taking part in the study? 
There are no long-term risks to you from participating in this study.  The specific 
risks associated with each investigation are as follows: 
1.  Blood samples: 
The risks of drawing blood include temporary discomfort from the needle stick 
and bruising. 
2.  Echocardiogram: 
There is no risk to their health from an Echo, however, if they have chest wall 
injuries, they may find the procedure a little uncomfortable.  We will give them 
painkillers if this is the case and only proceed when they are happy for us to do 
so. 
What are the possible benefits of taking part in the study? 
In the event that we detect an abnormality with your relative/significant other’s 
heart, we will refer them with your consent to a specialist in order to ensure they 
get appropriate care and follow up.  In addition, we hope that the information we 
get will help to improve the care of trauma patients in the future. 
What if there is a problem? 
Any complaint about the way you or your relative have been dealt with during the 
study or any possible harm they might suffer will be addressed.  The detailed 






Will taking part in the study be kept confidential? 
Yes.  We will follow ethical and legal practice and all information about your 
relative/significant other will be handled in confidence.  The details are included 
in Part 2. 
This Completes Part I. 
If the information in Part 1 has satisfied you and you are considering continuing in 
the study, please read the additional information in Part 2 before making any 
decision. 
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PART 2 
What will happen if I don’t want them to carry on with the study? 
If you or your relative/significant other decides, at any time, to withdraw from the 
study all study procedures will be stopped immediately.  Any information and 
samples that have already been collected will be processed as part of the study 
unless you wish to have their samples withdrawn from the study, in which case 
we will destroy them.  Your decision will in no way result in a change in the type 
or quality of care they subsequently receive. 
What if I am not happy about the study? 
We will only make very minor changes to the way we look after your 
relative/significant other.  It is extremely unlikely that this small change to normal 
practice would cause any problems.  However, if they are harmed by taking part 
in this study, there is no special compensation arrangement.  If they are harmed 
due to someone’s negligence, then you may have grounds for legal action but 
you may have to pay your legal costs.  Regardless of this, if you wish to complain 
or have any concerns about any aspect of the way you or your relative have been 
approached or treated during the course of this study, the normal National Health 
Service complaints mechanisms should be available to you.  Please contact 
Patient Advisory Liaison Service (PALS) if you have any concerns regarding the 
care they have received, or as an initial point of contact if you have a complaint.  
Please telephone 020 7377 6335, minicom 020 7943 1350, or email 
pals@bartsandthelondon.nhs.uk.  You can also visit PALS by asking at any 
hospital reception. 
Will taking part in the study be kept confidential? 
All information collected during the course of the research will be kept strictly 
confidential and will be stored securely in coded form.  If you consent to take part 
in the research the people conducting the study will abide by the Data Protection 
Act 1998, and the rights you and your relative have under this Act.  Only 
authorised personnel such as researchers and research auditors will have 
access to the data.  Any subsequent use of the samples will have to be 
performed with approval from a research ethics committee, otherwise the 
samples will be destroyed.  
What will happen to the samples that are given? 
We would like your permission to store his/her blood samples for further 
research.   Any further use of the samples outside of this research study will have 
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What will happen to the results of the research study? 
We hope to publish the results in a scientific journal. It will not be possible to 
identify any individual who has taken part from this scientific report.  Copies of 
the report will be available on request. 
Who has reviewed the study?  
All research in the NHS is looked at by independent group of people, called a 
Research Ethics Committee to protect your safety, rights, wellbeing and dignity. 
This study has been reviewed and given ethical approval by the Cambridgeshire 
3 Research Ethics Committee. 
Who can I contact for further information? 
1. If you require further information about the study, please contact the ACIT 
Study offices via the Trauma Surgery secretary at 020 7377 7000, 
ext7695 or email: Henry.De’Ath@bartsandthelondon.nhs.uk 
 
2. If you require impartial, local advice, please contact the Patient Advice 
and Liaison Service, telephone: 020 7943 1335 or e-mail: 
pals@bartsandthelondon.nhs.uk 
Thank you for taking the time to read this sheet.  
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Appendix V 
Trauma Associated Cardiac Injury and Dysfunction (A) 
 
Trauma patients are eligible for participation in TACID A trial unless they 
meet one of the following: 
 
x Patients transferred from other hospitals 
x Not expected to survive <72 hours  
x Pregnant 
x Patients <16  
x Prisoners 







Patient Name  _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _   
 
 
Patient ID _ _ _ _ _ _ _ _ _ _ _ _ 
 
 
DOB  _ _/_ _/__    Approximate Age _ _ 
 
 
Date Recruited _ _/_ _/_ _ Time of Baseline Blood/ECG   _:_  
 
I, as trauma team leader, fully understand the TACID A research study 
and informed consent process.  I have read the consent documents and 
have provided consent in my capacity as a professional legally appointed 




Name  _ _ _ _ _ _ _ _ _ _ _ _ _ _  Title _ _ _ _ _ _ _ _ _ 
 
 








Appendix VI   
 
DIRECTORATE OF SURGERY AND ANAESTHESIA 
ROYAL LONDON HOSPITAL, WHITECHAPEL, LONDON E1 1BB 
 
Consent Form A – Subject 
Version 1.2, 02.06.2010            
 
Cambridgeshire 3 Research Ethics Committee 
REC number:  10/H0306/47 
 
Title:  TRAUMA ASSOCIATED CARDIAC INJURY AND DYSFUNCTION (A) 
Principal Investigator:  Mr. Karim Brohi, FRCS FRCA    
Please initial box to 
indicate agreement 
 
1. I confirm that I have read and understood the information sheet dated 30.07.2010 
(version 1.2) for the above study and have had the opportunity to ask questions.  I have  
been given a copy of the patient’s information sheet to keep.   [  ] 
2. I understand that my participation in this study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal rights 
being affected.        [ ] 
3. I understand that sections of any of my medical notes may be looked at by professional 
individuals involved in this study or by regulatory authorities where it is relevant to my 
taking part in research.  I give permission for these individuals to have access to my 
records. I understand that my personal data will be processed and stored securely in 
compliance with the 1998 Data Protection Act.  [ ]  
4. I agree to take part in the above study.    [ ] 
 
 
                   
Name of patient    Date    Signature 
 
 




                                
Name of person taking consent  Date    Signature 
(if different from Investigator) 
 
 
                    











Appendix VII     
 
 
DIRECTORATE OF SURGERY AND ANAESTHESIA 
ROYAL LONDON HOSPITAL, WHITECHAPEL, LONDON E1 1BB 
 
Consultee Declaration Form C 
Version 1.2, 30.07.2010            
 
Cambridgeshire 3 Research Ethics Committee 
REC number:  10/H0306/47 
 
Title:  TRAUMA ASSOCIATED CARDIAC INJURY AND DYSFUNCTION (A) 
Principal Investigator:  Mr. Karim Brohi, FRCS FRCA    
Please initial box to 
indicate agreement 
 
1. I confirm that I have read and understood the information sheet dated 30.07.2010 
(version 1.2) for the above study and have had the opportunity to ask questions.  I have  
been given a copy of the consultee information sheet to keep.  [  ] 
2. I understand that his/her participation in this study is voluntary and that I am free to 
withdraw him/her at any time, without giving reason, without their medical care or legal 
rights being affected.       [ ] 
3. I understand that sections of any of his/her medical notes may be looked at by 
professional individuals involved in this study or by regulatory authorities where it is 
relevant to them taking part in research.  I give permission for these individuals to have 
access to his/her records. I understand that his/her personal data will be processed and 
stored securely in compliance with the 1998 Data Protection Act.  [ ] 
4. I agree to allow my relative/significant other take part in the above study. [ ] 
 
 
         
Name of Patient   Relationship 
 
                   
Name of Consultee   Date   Signature 
 
 




                                
Name of person taking consent  Date   Signature 
(if different from Investigator) 
 
 
                    
Investigator    Date                Signature 
 
 
 
